Curriculum Vitae

Kenneth R. Shroyer, M.D., Ph.D. The Marvin Kuschner Professor and Chair, Department of Pathology

President, Stony Brook Pathologists, UFPC Vice Chair, Board of Directors, SB Clinical Practice Management Plan, Inc.

Renaissance School of Brook Medicine Stony Brook University, State University of New York

Date & Place of Birth: January 18, 1956, New Haven, CT Home Mailing Address: 141 Main St., Setauket, NY 11733 Home Telephone: (631)-675-6991 Office Telephone: (631)-444-3069 Higher Education From To Degree & Date Institution & Location Field 1974 1978 BA 06/05/78 Colorado College Biology 1978 1983 PhD 12/22/83 University of Colorado Pathology 1983 1987 MD 05/23/87 University of Colorado Medicine 07/23/88 06/22/88 Intern University of Colorado Pathology 07/01/88 06/30/91 Resident University of Colorado Pathology 1992 Cytopathology Summer Fellow, Radiumhemmet, Karolinska Institute, Stolkholm,

Sweden 2012 Program for Chiefs of Clinical Services, Department of Health Policy and Management

and the Center for Continuing Professional Education, Harvard School of Public Health, Boston, MA

Certification & Licensure DATE Agency 07/01/88 National Board of Medical Examiners, Certificate No. 349342 11/20/91 The American Board of Pathology (Anatomic and Clinical Pathology), Certificate No. 91-410 (voluntary recertification awarded 01/01/14-01/01/24) 07/10/95 The American Board of Pathology (Cytopathology), Certificate No. AQ-95-120 10/13/88 Colorado State Board of Medical Examiners, License No. 29153 11/8/07 New York State Medical License No. 60 246750 Academic Appointments Dates From To Title Institution & Location 1989 1991 Instructor Department of Pathology, SOM, Univ. of Colorado Health Sciences Center, Denver 1991 1997 Assistant Professor Department of Pathology, SOM Univ. of

Colorado Health Sciences Center, Denver 1997 2002 Associate Professor (tenured) Department of Pathology, SOM, Univ. of Colorado Health Sciences Center, Denver 2002 2007 Professor (tenured) Department of Pathology, SOM, Univ. of Colorado Health Sciences Center, Denver 2007 present Professor and Chairman (tenured) Department of Pathology, Stony Brook University

Medical Center, Stony Brook, NY 2015 present Professor (voluntary) School of Nursing, Stony Brook University Other Appointments Dates From To Title Institution & Location 1991 1998 Graduate Faculty Member Tumor Experimental Pathology, Graduate School, SOM, University of Colorado Health Sciences Center 1998 2007 Graduate Faculty Member Biomedical Sciences Program, Graduate School, University of Colorado Health Sciences Center 2006 present Graduate Faculty Member Division of Basic Reproductive Sciences, Dept. of

OB/GYN, University of Colorado HSC 2007 present Graduate Faculty Member Molecular and Cellular Biology, Graduate School, Stony

Brook University 2011 present Graduate Faculty Member Molecular and Cellular Pharmacology Program, Stony

Brook University 2011 present Graduate Faculty Member Graduate Program in Molecular Genetics & Microbiology,

Stony Brook University 2008 present Graduate Faculty Member Institute for Chemical Biology and Drug Discovery, Stony

Brook University 2012 present Director Cancer Research Program, Institute for Chemical Biology

and Drug Discovery, Stony Brook University 2007 present President Stony Brook Pathologists, UFPC 2012 present Member Internal Executive Committee and Advisory Boards,

Stony Brook Cancer Center. 2013 2016 Vice Chair SB Clinical Practice Management Plan, Inc. Board of

Directors, Stony Brook Medicine Professional Practice & Services Date Activity Location Institutional Affiliation 1991-2007 Surgical Pathology and University Hospital University of Colorado Cytopathology Health Sciences Center 1993-2007 Director of Cytopathology Department of Pathology University of Colorado Health Sciences Center 2000-2007 Director of Surgical Pathology Department of Pathology University of Colorado Health Sciences Center 2002-2006 Vice Chair for Anatomic Pathology Department of Pathology University of Colorado Health Sciences Center 2007-present Surgical Pathologist and Department of Pathology Stony Brook Medicine Cytopathologist

Professional & Scientific Societies Organization Date of Initial Membership Leadership Position(s) & Date American Society of Clinical Pathologists 1991 United States and Canadian Academy of Pathology 1991 Member of the Scientific Advisory Board,

Technology (2008-2011), Cytopathology (2009, 2011) American Association for Cancer Research 1991 American Society of Cytopathology 1993 American Society for Investigative Pathology 2002 Nominee, Program Chair-elect, 2019 International Society of Gynecologic Pathologists 2001 Arthur Purdy Stout Society of Surgical Pathologists 2002 College of American Pathologists 1991 Suffolk County Medical Society 2013 Medical Society of the State of New York 2013 International Soc for IHC and Molecular Morphology 2016 Academic & Professional Honors 2018 Pancreatic Cancer Action Network Translational Research Award 2016 Flame of Appreciation, Institute of Chemical Biology and Drug Discovery, Stony Brook University 2014 Excellence in Teaching Award, Department of Pathology, Stony Brook University 2009-2011 Pathology Research International, Editorial Board Member 2009-14, 17 Best Doctors in America 2009 Recognition for authorship of one of Human Pathology’s top 10 cited articles 2008-2011 Member of Scientific Review Board, Technology, United States and Canadian Academy of

Pathology 2007-presen The Marvin Kuschner endowed Professor, Stony Brook University 2004-present Human Pathology, Editorial Board Member 2006-present Journal of Clinical Virology, Associate Editor 2009 Journal of Clinical Virology, HPV Supplement Guest Editor 2003 Excellence as Unit Director Award (MSTP/GS Alternate Track, Pathology 6000) 1999 Max Kade Austrian Scholarship Award, accorded to Dr. Rainer Lehner, based on our work on

Analysis of Survivin and Telomerase Expression in Placental Development and Endometrial Neoplasia.

1998 Lucien J. Rubinstein Award for the Best Paper on Neuro-oncology. Shared with B.K. Kleinschmidt-DeMasters and MA Bitter. The American Association of Neuropathologists 1996-01 Excellence in Teaching Award (MSTP/GS Alternate Track, Pathology 6000), awarded annually 1997-01 Excellence as Unit Director Award (MSTP/GS Alternate Track, Pathology 6000), awarded annually 1996 Pathology Excellence in Teaching Award (Pathology 6000) 1993 Shannon Award in Biomedical Research, National Institutes of Health 1991 Robert H. Fennell, Jr., M.D. Award, Department of Pathology, UCHSC 1991 Pathology Small Group Teacher's Award (Pathology 6000) 1991 Chief Resident, Department of Pathology, UCHSC 1991 Colorado Society of Clinical Pathology Resident's Award

1987 Graduation with Honors, University of Colorado, School of Medicine 1989 Colorado Society of Clinical Pathology Resident's Award 1986-87 Edgar and Marion Adler Scholar Award, UCHSC 1987 Joseph and Regina Glaser Student Research Award, UCHSC 1985-86 Edgar and Marion Adler Scholar Award, UCHSC 1984 Medical School Research Conference Award, UCHSC 1983-84 Academic Achievement Award, UCHSC 1983 Medical Student Travel Award, UCHSC, to attend annual meeting of International Society of Cell Biology, Tokyo, Japan Date National/International Study Section Member 2000 Department of Veterans Affairs, Office of External Reviewers, Merit Review 2001 National Cancer Institute, Study Section, RFA 02-001 Tissue and Biological Fluid Banks of HIV- Related Malignancies, Rockville, MD, October 19

2002 Department of Veterans Affairs, Program Review Division, Merit Review 2003 Department of Veterans Affairs, Program Review Division, Merit Review 2004 National Cancer Institute, RFA RFA-CA-04-015, Strategic Partnering to Evaluate Cancer Signatures, November 18-19

2005 National Cancer Institute, SPORE (Specialized Programs of Research Excellence), Ovarian and Gynecologic Cancers, April 19-20 2005 National Cancer Institute, Innovative Molecular Analysis Technologies (IMAT), October 18-19 2006 National Cancer Institute, Applied Emerging Technologies for Cancer Research, March 16-17 2006 National Cancer Institute, Applied Emerging Technologies for Cancer Research, June 20-21 2006 National Cancer Institute special emphasis panel (SEP), Alliance of Glycobiologists for Detection

of Cancer and Cancer Risk, November 8-9.” 2007 National Cancer Institute, Applied Emerging Technologies for Cancer Research, March 3-4 2007 National Cancer Institute, Innovative Molecular Analysis Technologies (IMAT), June 27-28 2008 National Cancer Institute, Application of Emerging Technologies in Cancer Research (IMAT),

February 6-7. 2008 National Cancer Institute, Specialized Program in Research Excellence (SPORE), February 12-13. 2008 National Cancer Institute, Application of Emerging Technologies in Cancer Research (IMAT),

March 18. 2008 National Cancer Institute, Application of Emerging Technologies in Cancer Research (IMAT),

June 26. 2008 National Cancer Institute, Application of Emerging Technologies in Cancer Research (IMAT),

October 14. 2009 National Cancer Institute SPORE (Specialized Programs of Research Excellence) applications in

ovarian and gynecological cancers, February 11-12. 2009 National Cancer Institute, RFA-OD-09-003, Challenge Grants, June 5, 2009. 2009 National Cancer Institute, IMAT, Application and Use of Transformative Emerging Technologies

in Cancer Research” (RFA-CA-09-006 and RFA-CA-09-007), June 23-24. 2009 National Institutes of Health, Division of Physiological & Pathological Sciences, Member Conflict

Immunology Special Emphasis Panel [ZRG1 IMM-J(02)M], October 27. 2010 National Cancer Institute, SPORE (Specialized Programs of Research Excellence) applications in

Breast, Ovarian, and Skin Cancers. February 17-19.

2010 National Cancer Institute, Cooperative Group Banks (CGBs), RFA CA09-504 Support for Human Specimen Banking in NCI-Supported Clinical Trials. March 2.

2010 National Institutes of Health, Cancer Prevention, Member Conflict Immunology Special Emphasis Panel [ZRG1 OTC-B02], September 3.

2010 American Association for the Advancement of Science, Research Competitiveness Program. December 8.

2010 Health Research Council of New Zealand. International Investment Opportunities Fund for Cancer Research.

2011 National Institutes of Health, In Vivo Cellular and Molecular Imaging Centers (ICMICs), March 15-16.

2011 National Institutes of Health, Emerging Technologies for Cancer Research, March 29-30 2011 National Cancer Institute, SPORE (Specialized Programs of Research Excellence), applications in

Lymphoma, Breast, Ovarian, Genitourinary and Gastrointestinal Cancers, June 9-10 2011 National Cancer Institute, Indo-US Collaborative Program on Low-Cost Medical Devices, October

19-20 2011 National Cancer Institute, Cancer Target Discovery and Development (CTDD) Network (U01),

November 14-15 2012 National Cancer Institute, Indo-US Collaborative Program on Low-Cost Medical Devices,

February 15-16 2012 National Cancer Institute, Research Answers to NCI’s Provocative Questions, March 7 2012 Chair, National Cancer Institute, RFA CA12-501, The Chernobyl Tissue Bank-Coordinating

Center, June 13. 2012 National Cancer Institute, RFA CA-12-003, IMAT applications (Validation and Advanced

Development of Emerging Technologies for Cancer Research), June 14. 2012 National Cancer Institute Small Grants Program for Cancer Research (NCI Omnibus R03; PAR-

12-144) and Exploratory/Developmental Research Grant Program (NCI Omnibus R21; PAR-12-145), Oct 29-30.

2013 Chair, National Cancer Institute, RFA CA13-005 AIDS and Cancer Specimen Resource (ACSR), May 29.

2013 National Cancer Institute, Cancer Diagnostics and Treatments (CDT) SBIR/STTR, June 27-28. 2013 National Cancer Institute, Indo-US Collaborative Program on Low-Cost Medical Devices, July 31-

August 1. 2014 National Cancer Institute, Omnibus SEP-11, November 18. 2015 National Cancer Institute, IMST-M (02) EBIT Member Conflict review panel, February 26. 2015 National Cancer Institute SPORE (Specialized Programs of Research Excellence) applications in

Breast and Ovarian Cancers. June 8-9. 2016 National Cancer Institute SPORE (Specialized Programs of Research Excellence) applications in

Breast, Endometrial, and Ovarian Cancers, February 30. 2016 National Cancer Institute, Provocative Questions Initiative, April 8. 2017 RMATRIX Program, University of Hawaii, March 20-24. 2017 Chair, National Cancer Institute, RFA CA16-502, Limited Competition: The Chernobyl Tissue

Bank – Coordinating Center, May 2. 2017 National Cancer Institute, RFA-CA-17-023, Integration and Validation of Emerging Technologies

to Accelerate Cancer Research (R33), Beau Biden Cancer Moonshot Initiative, National Cancer Institute Special Emphasis Panel, Emerging Technologies Review II, July 10-12.

Clinical Faculty Recruited, Stony Brook Medicine, 2007- Present: Meenakshi Singh, MD 11/19/08- 5/11/2015- Professor, Chief of Surgical Pathology, and Vice Chair for

Anatomic Pathology, Stony Brook Medicine Yupo Ma, MD, PhD 2/1/2010- Professor, Medical Director of Flow Cytometry Lab, Stony Brook

Medicine, Director of Stem Cell Core, Stony Brook Medicine Mark Lusco, MD 8/5/2013- 8/1/2014- Assistant Professor and Renal Pathologist Ming Wu, MD 12/8/2010- 2/1/2013- Assistant Professor and Renal Pathologist Jela Bandovic, MD 3/20/2015- Associate Professor and Chief of GI Pathology, Director of the Gross

Anatomic Pathology and Histology Labs Daniel Mockler, MD 7/1/2017 Clinical Assistant Professor, Chair, Department of Pathology,

Southampton Hospital Adela Cimic, MD 9/1/2015- 5/20/2016- Clinical Assistant Professor, Chief of Renal Pathology, Maoxin Wu, MD, PhD 9/2/2014- Clinical Professor, Chief of Cytopathology, Director of Fine Needle

Aspiration and Core Biopsy Services. Daniel Lozeau, MD 6/1/2015- Clinical Assistant Professor, Dermatopathology, Department of

Pathology and Dermatology, Xiaotong (Tony) Wang, MD 9/12/2016- Clinical Assistant Professor Assistant Professor and Renal

Pathologist Chiraag Patel, MD 5/15/2017- Assistant Professor, Chief of Molecular Pathology Rebecca Batiste, MD 4/30/2017- Clinical Assistant Professor, Surgical Pathologist Michael Caplan, MD 11/3/2014- Part Time Associate Professor, Department of Pathology, Chief

Medical Examiner, Suffolk County Medical Examiner’s office James Davis, MD 7/1/2012- Clinical Assistant Professor, Surgical Pathologist, Pediatric

Pathologist, Neuropathologist, Medical Director of the Stony Brook Biobank Hong Lin Smith-Jones, PhD 8/1/2018- Chief of Clinical Immunology Amit Gokhale, MD 8/1/2018- Clinical Assistant Professor, Chief of Transfusion Medicine Brendan Boyce, MD, ChB 12/4/2018-Professor and Chief of Bone and Soft Tissue Pathology, Department

of Pathology Research Faculty Recruited, Stony Brook Medicine, 2007- Present: Jingfang Ju, PhD 7/1/2008- Professor, microRNAs in cancer Haojie Hwang, PhD 2012-2013Associate Professor, basic and translational research, prostate cancer Glenda Trujillo, PhD 4/27/2010-11/14/2014- Assistant Professor, basic and translational research, GI

cancer Natasha Marchenko, PhD 10/15/2011- Assistant Professor, p63 in breast cancer Jian Chen, MD 5/1/2012- Associate Professor, planar cell polarity research, skin cancer Geoffrey Girnun, PhD 11/11/2013- Joint recruitment with Cancer Center, Associate Professor, Director

of Metabolomics, Cancer Center John Haley, PhD 4/2/2014- Joint recruitment with Cancer Center, Associate Professor, Director of

Developmental Therapeutics, Cancer Center, Director of Proteomics Core Scott Powers, PhD 5/1/2014- Joint recruitment with Cancer Center, Professor, Director of Clinical

Cancer Genomics, Cancer Center, Angelique Corthals, PhD 9/1/2012- 5/30/2015 Assistant Professor, Scientific Director of Stony Brook

BioBank Patricia Thompson, PhD 10/7/2014- Joint recruitment with Cancer Center, Professor, Deputy Director of

the Stony Brook Cancer Center, Pathogenesis of colorectal and breast cancer

Luis Martinez, PhD 8/3/2015- Joint recruitment with Cancer Center, Associate Professor, basic and translational research, p53 in cancer

Jun Chung, PhD 5/1/2015- Joint recruitment with Cancer Center, Associate Professor, mechanisms of cancer invasion and metastasis

Flaminia Talos, MD, PhD 9/1/2015- Joint recruitment with Cancer Center and Department of Urology, Assistant Professor, clonal evolution of cancer

Vincent Yang, MD, PhD 9/1/2011-Professor and Simons Chair, Department of Medicine Stony Brook Medicine, Professor, Physiology & Biophysics Jenya Alexandrova, PhD 7/1/2016- Joint recruitment with Cancer Center, Assistant Professor, p63 in

breast cancer Adam Rosebrock, PhD 9/15/2016- Joint recruitment with Cancer Center and Department of

Biochemistry, Assistant Professor, cancer metabolomics Luisa Escobar-Hoyos, PhD 3/1/2016- Research Assistant Professor, Co-Director of Pathology Translational

Research Laboratory Lucia Roa, MD 1/12/2017- Research Instructor, Department of Pathology Alice Nemajerova, PhD 6/28/2017- Research Professor, Department of Pathology Richard Moffitt, PhD 8/01.17- Joint recruitment with Cancer Center and Department of Biomedical

Informatics, Assistant Professor, molecular subtyping of pancreatic cancer David Montrose, PhD 12/14/2018- Joint recruitment with Cancer Center, Assistant Professor, serine

metabolism and chemoresistance in cancer Community Service and Awards 2008-present Member, Research Corporation of Long Island, Inc. (RCLI) Board of Directors 2008-2009 Maryland Technology Development Corporation (TEDCO), scientific reviewer 2009-present Long Island Research Association Invitational Science Fair, judge for high school scientific poster presentations 2011-2015 Member, External Advisory Board, National Cancer Institute Pathobiology of Cancer Training

Grant, Johns Hopkins University School of Medicine 2011-2015 Member External Advisory Board, National Institutes of Health, National Center for Research

Resources, University of Hawaii 2015 ZRG1 IMST-M (02) B Center for Scientific Review Special Emphasis Panel, February 26. 2017 Inducted into the Hall of Honor, Pueblo Central High School Research Support: Grants, Contracts (2007-present) From To Project & Sponsor Amount 07/01/06 - 06/30/11 National Cancer Institute, R01 Salivary acinar cell apoptosis: Annual direct costs Regulation of p53 by Akt. Steve Anderson, PI, Kenneth $336,633 R. Shroyer, Co-I. 01/01/07-12/31/08 National Cancer Institute, RCA125370A Specific Biomarkers for Detection of Cervical Cancer Cells Using Flow Cytometry score, J. Paul Robinson, PI, Kenneth R. Shroyer, Consultant. 01/01/07-06/22/09 TriPath Imaging Inc. Molecular Pap Intended Use Clinical Total project costs Trial. 2-5-90121 Kenneth R. Shroyer, PI, $486,192

06/21/06-06/20/07 The Office of Interdisciplinary Research in Women’s Health Total project costs Reproductive Science. Molecular Imaging of CA-125 in Ovarian $13,200 Carcinoma Cells. Conrad Stoldt, PI, Kenneth R. Shroyer, Co-PI.

02/01/07-01/31/08 Rexinoid Therapy for Poorly Differentiated Thyroid Cancer: $20,000 A Pilot Clinical Trial and Correlation to Retinoid and PPARα Receptor Expression. American Cancer Society Institutional Research Grants/ University of Colorado Cancer Center Joshua Klopper and Kenneth R. Shroyer. 04/01/07-12/31/07 CFD Therapeutics. Immunohistochemical Validation of Candidate Total Project Costs

Biomarkers of Endometrial, Ovarian, and Pancreatic Carcinoma. $10,000

08/01/04-04/30/10 National Cancer Institute, Total direct costs R21/R33 CA110519-01/4R33CA110519-02. Phased innovation $551,888 and application award. p16 and HPV in low-grade cervical cytologic specimens. Kenneth R. Shroyer, PI. 11/03/08-11/02/09 Targeted Research Opportunities, Carol M. Baldwin Breast Cancer Total Project Costs Research Award. Multifunctional Carbon Nanostructure-Based $80,000 Platforms for Breast Cancer Theragnostics, Balaji Sitharaman, PI, Kenneth R. Shroyer, Co-I. 11/03/08-11/02/09 Targeted Research Opportunities, Proteomics Developmental Total Project Costs Projects Award, Richard Kew, PI, Kenneth R. Shroyer, Co-I. $20,000 10/01/09-09/30/13 Department of Veteran’s Affairs Merit Review (Zucker) Total Project Costs Reversibility of Epithelial Mesenchymal Transition in Prostate $650,000 Cancer. Kenneth R. Shroyer, Co-I. 07/01/10-06/30/13 Department of Defense. (Sitharaman), Tumor-targeting single- Total Direct Costs wall carbon nanotubes for microwave-based imaging and $293,000 hyperthermia treatment of breast cancer: A small animal study. Kenneth R. Shroyer, Consultant. 2009-2010 Targeted Research Opportunities, Carol M. Baldwin Breast Total Direct Costs Cancer Research $30,000 Award. Evaluation of a Newly Designed Device for Breast Cancer Screening. Barbara Nemasure, PI, Kenneth R. Shroyer, Co-I. 2009-2010 Targeted Research Opportunities, Proteomics Developmental Total Direct Costs Projects Award. Identifying Biomarkers for Pre-malignant and $15,000 Invasive Cervical Cancer. Kenneth R. Shroyer, PI, Emily Chen, Co-I.

07/01/04-06/30/10 NIH/NIDDK 2R01-DK059265. (Pan) Noninvasive Detection of Urothelial Abnormalities Kenneth R. Shroyer Co-I (since 2010) 09/08/10-08/31/13 NIH. 1R33CA140084-01A1 (Robinson, Shroyer subcontract PI) Total Direct Costs Specific Detection of Cervical Cancers Using Cytometry- $404,913 Based Molecular Diagnostics. 2009-2010 Targeted Research Opportunities, Proteomics Developmental Total Direct Costs Projects Award. Using Metastatic Breast Cancer Stem Cells $35,000 To Predict The Risk Of Recurrence and Metastasis

In Breast Cancer Patients. Emily Chen, PI, Kenneth R. Shroyer. Co-I

08/01/11-07/31/14 Coulter foundation. Pre-clinical Evaluation of Carbon Total Direct Costs Nanostructure-Based High-Performance Contrast Agent for $410,000 Magnetic Resonance Imaging. Balaji Sitharaman, PI, Kenneth R. Shroyer (Clinical PI)

01/02/12-01/31/16 NIH grant, R01CA084197. Mechanisms of Intestinal

Tumorigenesis, Vince Yang, PI, Kenneth R,. Shroyer, Consultant

07/01/13-06-30/14 Targeted Research Opportunities-FUSION Award. Novel Total Direct Costs Graphene-Based MRI Contrast Agent for Renal Imaging. $40,000

Balaji Sitharaman, PI, Kenneth R. Shroyer. Co-I 9/25/13- 08/24/14 STTR phase 1, National Institute of Health

Preclinical Efficacy and Safety Evaluation of Graphene Nanoparticle-based Magnetic Resonance Imaging Contrast Agent for Diagnosis of Renal Failure Dr. Balaji 7 PI Kenneth R. Shroyer, Co-I

07/01/14-06/30/19 NIH/NCI (Hannun) 2 P01 CA097132-11A1 Total direct Costs: Sphingolipids in Cancer Biology and Therapy $892,069

Project 1: Role of Acid Sphingomyelinase in Breast Cancer Project leader: Yusuf Hannun, Direct Cost budget $142,088 Kenneth R. Shroyer, Co-I, 0.60 calendar months

Project 2: Tumor Suppressive Role of ACER1 in Skin Cancer Project leader: Cungui Mao, Direct Cost budget $137,965 Kenneth R. Shroyer, Co-I, .24 CM

Sphingolipid Cancer Animal Pathobiology Core Total Direct Costs: Director: Ashley Snider; Direct Cost budget $172,747 $100,593

Kenneth R. Shroyer, Co-I, .60 CM Total effort: 1.44 CM

07/01/14-06/30/16 Targeted Research Opportunity Program – Carol M. Baldwin Total Direct Costs:

Foundation for Breast Cancer Research Vitamin-Taxoid Drug Conjugate towards IND Filing $70,000

Iwao Ojima (PI), Kenneth R., Shroyer (Co-I) 10/1/14-9/30/15 Cook Biotech Inc. Award #: 70100, Project#: 1122003 Total Direct Costs:

Tissue Remodeling in Hiatal Hernia Repair: The Effect of $196,130 Adipose Derived Mesenchymal Stem Cells and Platelet Rich Plasma Dana Telem (PI), Kenneth R. Shroyer (Co-I)

10/31/14 -9/30/15 Babylon Breast Cancer Coalition. Development of a genomic Total Direct Costs:

test for early detection of high-grade serous ovarian cancer $12,500 (Michael Pearl, Scott Powers, Kenneth R. Shroyer, Co-PIs)

07/01/13 - 04/30/18 NIH/NCI 1R01CA172113-01A2

Targeted Approach for Prevention and Therapy of Colorectal Cancer The major goals of this project are to define the mechanism of action of our inhibitors of the expression of the colorectal-cancer-linked transcription factor KLF5. Vincent W. Yang (PI), Kenneth R. Shroyer (Consultant)

07/01/15 - 06/30/17 NIH/NCI R21 PAR-13-146

Development of a genomic test for early detection of high-grade serous ovarian cancer. The goal of this project is to develop a genomic test to identify HG-SOC cells in the uterine cavity. Scott R. Powers (PI), Kenneth R. Shroyer (Co-I)

3/01/15 -2/28/16 SBIR phase 2, National Institute of Health

Preclinical Efficacy and Safety Evaluation of Graphene Nanoparticle-based Magnetic Resonance Imaging Contrast Agent for Diagnosis of Renal Failure

Jimmy Toussaint (PI), Kenneth R. Shroyer (Consultant) 5/19/15- 4/30/17 NIH/NCI R01CA195506 Assessing the Role of [11C]Vorozole in the Detection of Aromatase

in Breast Cancer. Anat Biegon (PI), Jules Cohen (PI), Kenneth R. Shroyer (Co-I)

8/1/15- 7/30/20 1R01CA192407-01A1 Detection of metastases in lymph nodes using Total Direct Costs:

quantitative ultrasound $448,966 Ernest Feleppa (PI) (Stony Brook subcontract)

Kenneth R. Shroyer (Co-I), 0.24 calendar months. 10/27/16-10/26/17 2 one-day symposia on “ Chemical Biology and Drug Total Direct Costs: Discovery” Joint Symposium, Stony Brook University $30,000

and Icahn School of Medicine at Mt. Sinai Kenneth R. Shroyer (Multiple PI with Iwao Ojima) 2/7/17-2/6/18 Stony Brook Medicine-Icahn School of Medicine at Total Direct Costs:

Mount Sinai Joint Pilot Funding program. $50,000 Computational Tools for High Dimensional Spatial Analysis of Multiplex Immunohistochemistry Data.

Joel Saltz (PI), Kenneth R. Shroyer (Co-I) 07/26/17-06/30/19 Targeted Research Opportunity Program – Carol M. Total Direct Costs:

Baldwin $70,000 Foundation for Breast Cancer Research Multifunctional Nanomaterials for Breast Cancer Theranostics

Kenneth R., Shroyer (PI) 07/01/18-06/30/20 Pancreatic Cancer Action Network Total Direct Costs:

Translational Research Grant 18-65-SHRO $500,000 Keratin 17 is a novel actionable target in pancreatic ductal adenocarcinoma Kenneth R. Shroyer (PI), 1.2 calendar months

Inventions and United States Patent: Dinitro-phenyl (DNP) labeling of nucleic acids and use for mRNA In Situ Hybridization

K.R. Shroyer J. Cell Biol. 97:377, 1983., International Cell Biology 1984 (S. Seno and Y. Okada, eds.), Academic Press

Japan, Inc., Tokyo, p. 457, 1984. Method of identifying clonal cell samples Co-Inventor Jay Stoerker, Avitech Diagnostics, Malvern, PA Patent Number 5843649 Issue Date 12/01/1998

OVR110 (B7-H4) Antibody Compositions and Methods of Use Patent number: 7964195 Filed Jan 9, 2006 Issue Date June 21, 2011 Assignee: Diadexus, Inc. Inventors: Jackie Papkoff, Kenneth R. Shroyer

Micropunch Biopsy Device and Method No. 435760; CU1305B

Co-inventor with Y.C. Lee and A. Mickelson, School of Engineering, CU Boulder Filed July, 2005 Cytokine IL-32 and Cutaneous Diseases: Prediction, Diagnosis and Treatment

Co-inventor with L.-J. Hu, E.K. Callaway, J.E. Fitzpatrick, M.K. Takashi, L. Li, T.K. Azam, S.-H.K. Kim, C.A. Dinarello, D.A. Norris, and C.K. Edwards Filed with University of Colorado Technology Transfer Office May, 2006 Multiexcitation Diagnostic Systems and Methods Co-inventor with P.N. Werahera, A. Mickelson, E. McKenna, J. Daily, M.S. Lucia, E.D. Crawford, Y.C. Lee, A.D. Meyers, V. Sivashankar. Filed April, 29, 2006 Application no. 60/676/420

Shroyer, K, Escobar-Hoyos, L.F, Chen, E. Keratins as Biomarkers for Cervical Cancer and Survival. Stony Brook University Research Foundation. Pending International PCT Application WO2015021346-A1. Published 02/12/2015, file date of the PCT application 8/8/15. Provisional filed on 8/14/13. Nationalized in Brazil, EU (EP 3030679 A1), China (CN 105899673A), India (201617003665 A) and US (US2016/0187341-A1). Licensed to OncoGenesis. Shroyer, K, Escobar-Hoyos, L.F, "Keratins as Biomarkers for Head and Neck Cancers". Stony Brook University Research Foundation. Pending International PCT Application No. WO 2015/175858. Nationalized in the US only. Shroyer, K, Escobar-Hoyos, L.F. Keratin 17 as a Drugable Target for Cancer Treatment. Stony Brook University Research Foundation. Filed 5/5/15. Published as WO 2016/141269 on 9/9/2016. Licensed to OncoGenesis. Shroyer, K, Escobar-Hoyos, L.F. Keratin 17 as a Prognostic and Predictive Marker of Pancreatic Cancer. Stony Brook University Research Foundation. Filed 10/29/15. Pending Provisional Patent Application. Filed PCT on October 29, 2016. CDA with KDx. Shroyer, K, Escobar-Hoyos, L.F., Kim N. Keratin 17 as a biomarker for bladder cancer. Stony Brook University Research Foundation. KDx Diagnostics Inc. SBU Ref: R-8855 - conversion deadline; US Provisional Application No. 62/371,286; SSMP Docket: 33851P, International Publication number WO 2018/027091 A1

Biotechnology Consultant

Feb 2014-present Member, Scientific Advisory Board, OncoGenesis Corporation, Sunnyvale CA June 2015-2017 Member, Scientific Advisory Board, Theragnostic Technologies, Coram, NY January 2018-present Member, Scientific Advisory Board, KDx Diagnostics, Inc., Campbell, CA University and Hospital Service Date Activity 1995-1996 Faculty Senate, UCHSC

2002-2004 Faculty Senate, UCHSC 1997-1999 Curriculum Review Committee, Medical School Representative, UCHSC 1997- 2002 Fundraising Advisory Committee, UCHSC 1998 Fitzsimmons Redevelopment Program, Ancillary and Support Services Sub-Committee, UCHSC

1998-2001 Breast Cancer Program Development and Search Committee, UCHSC 1998-2002 Head and Neck Tumor Pathology Tumor Bank, Co-director 1998-2002 Faculty Promotions Committee, UCHSC 2001-2002 Fitzsimmons Inpatient Facility Planning Group, Pathology Group, Chair 2001 Search Committee, Chair for Department of Surgery, member 2001-2007 Cancer Committee, University of Colorado Hospital 2006-2007 Search Committee, Head of Division of Endocrinology, Department of Medicine, member 2006-2007 Faculty Senate, UCDHSC 2006-2007 Colorado Multiple Institutional Board, Anatomic Pathology Consultant, , UCDHSC 2007 Search Committee, Chair of Radiology, member, UCDHSC 2007- President, Stony Brook Pathologists, Inc. 2007- Bylaws Committee, Medical Board, Stony Brook University Hospital 2008- Member, Clinical Practice Management Plan, Stony Brook University Hospital, Board of

Directors 2008- Member, Stony Brook University Cancer Center Community Advisory Board 2008- CPMP Purchasing and Asset Management Committee 2008- Member, Institute of Chemical Biology and Drug Discovery, Stony Brook University 2008-2009 Member, Search Committee for Chair of the Department of Medicine

2009-2010 Member, LCME Self-study Educational Resources Subcommittee, Stony Brook University School of Medicine

2010-2011 Chair, Search Committee for Chair of Department of Medicine (recruited Dr. Vincent Yang)

2010-2012 Member, Honorary Degree Selection Committee, Stony Brook University 2009-2010 Member, Search Committee, Vice President for Research, Stony Brook University 2009- Member, Strategic Plan Steering Committee, Stony Brook University School of Medicine 2010- Member, Steering Committee, Institute of Chemical Biology and Drug Discovery, Stony

Brook University 2010- Member, Advisory Committee, Stony Brook University Wellness University 2011- Member, Bylaws Committee, Stony Brook University Hospital 2012- Search Committee Chair, Deputy Director for Research, Stony Brook Cancer Center 2012- Director, Institute for Chemical Biology and Drug Discovery Cancer Research Program,

Stony Brook University 2012- Member, Internal Advisory Board, Stony Brook Cancer Center 2012-2014 Member, Space Management & Utilization Committee (SMUC) 2012-2014 Elected member, Medical Executive Committee (MEC), Stony Brook Hospital Medical

Board 2012- Proteomics Core Advisory Committee, Stony Brook Medicine 2012- Genomics Core Advisory Committee, Stony Brook Medicine 2012- Internal Advisory Board, NIH program for Sphingolipids in Cancer, (PI Y. Hannun) 2012- Cancer Grand Rounds, committee member, Stony Brook Cancer Center

2013- Search Committee Member, Chief of the Division of Infectious Diseases, Department of Medicine, Stony Brook Medicine

2013- Member, Stony Brook University Information Enterprise Advisory Board (IEAB) 2014 Chair, Cancer Center Annual Retreat 2015- Chair, TRO Carol Baldwin Breast Cancer Research Award Review Committee. 2015- Chair, Institute for Chemical Biology and Drug Discovery 9th Annual Symposium. 2017- LCME Task Force, Member 2017- Member, Advisory Committee, Kavita and Lalit Bahl Center for Metabolomics and

Imaging 2013- Judge for oral poster presentations, Annual Research Retreat, Department of Surgery 2019 Judge for the Basic Science oral poster presentations, Department of Anesthesiology

Academic Research Evening

BIBLIOGRAPHY https://www.ncbi.nlm.nih.gov/sites/myncbi/kenneth.shroyer.1/bibliography/47427615/public/?sort=date&direction=ascending 1. K.R. Shroyer and P.K. Nakane. Immunohistochemical Localization of Albumin and In Situ Hybridization

of Albumin mRNA. Cell. Biochem. Function 5:1987, 195-210. 2. K.R. Shroyer, C.L. Williams, G.J. Miller and L.E. Gerschenson. Uteroglobin Production in the

Pseudopregnant Rabbit Uterus: Immunohistochemical Studies. Histochemistry 87:1987, 471-478. 3. K.R. Shroyer, R.L. Lieberman and L.E. Gerschenson. Estradiol-178 and Progesterone Regulate Secretion

of Uteroglobin Through Different Pathways. Histochemistry 87:1987, 173-179. 4. T.R. Beaver, K.R. Shroyer, C.A. Muro-Cacho, G.J. Miller and S.G. Blount. Survival to Age 65 Years

with Tricuspid and Pulmonic Valve Atresia. Am. J. Cardiol. 62:1988, 165-166. 5. K.R. Shroyer, J. Hosey, L.E. Swanson, W.D. Woodard and R.H. Fennell. Cytologic diagnosis of human

papillomavirus infection: Spindled nuclei. Diag. Cytopath. 6:1991, 54-59. 6. K.R. Shroyer, G.S. Svedlow and D.M. Adcock. Mycotic pseudoaneurysm of the thoracic aorta with

purulent pericarditis. Am. J. Cardiovasc. Path. 3:1991, 347-352. 7. K.R. Shroyer and R.O. Greer. Detection of HPV DNA by in situ DNA hybridization and polymerase

chain reaction in premalignant and malignant oral lesions. Oral Surgery, Oral Medicine and Oral Pathology 71:1991, 708-713.

8. K.R. Shroyer, J.G. Kim, C. Greer, M.M. Manos, N.W. Pearlman and W.A. Franklin. Polymerase chain reaction and in situ hybridization detect human papillomavirus DNA in anorectal squamous carcinoma, but not in colonic adenocarcinoma. Arch. Surg. 127:1992, 741-44. Abstracted in Papillomavirus Report 4:39-40, 1993.

9. J.A. Chorny, K.R. Shroyer and L.E. Golitz. Malignant melanoma and a squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. Arch. Dermatol. 129:1993, 1212.

0. K.R. Shroyer, G. Lovelace, M.L. Abarca, R.H. Fennell, M.E. Corkill, W.D. Woodard and G.H. Davilla. Detection of HPV DNA by in situ hybridization and polymerase chain reaction in HPV equivocal and dysplastic cervical biopsies. Hum. Pathol. 24:1993, 1012-1016.

11. I.Y. Chen, D.A. Lynch, K.R. Shroyer and M.J. Schwarz. Gaucher disease: An unusual cause of intrathoracic extramedullary hematopoiesis. Chest 104:1993, 1923-1924.

12. K.R. Shroyer, R.O. Greer, C.A. Fankhouser and W.F. McGuirt. Detection of human papillomavirus DNA in oral verrucous carcinoma by polymerase chain reaction. Mod. Pathol. 6:1993, 669-672.

13. Haugen, S. Nawaz, A. Cohn, K. Shroyer, P.A. Bunn, D.R. Liechty and E.C. Ridgway. Secondary malignancy of the thyroid gland: a case report and review of the literature. Thyroid 4:1994, 297-300.

14. K.R. Shroyer and E. Gudlaugsson. Determination of clonality in endometrial adenocarcinoma by PCR amplification of PGK-1. Hum. Pathol. 25:1994, 287-292.

15. T. Enomoto, M. Fujita, M. Inoue, O. Tanizawa, T. Nomura and K.R. Shroyer. Analysis of clonality by amplification of short tandem repeats: Carcinomas of the female reproductive tract. Diag. Mol. Pathol. 3:1994, 292-297.

16. T. Enomoto, M. Fujita, M. Inoue, T. Nomura and K.R. Shroyer. Alteration of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrioid adenocarcinoma from Colorado. Am. J. Clin. Pathol. 103:1995, 224-230.

17. R.B. Howard, K.R. Shroyer, T. Marcell, L.E. Swanson, M.E Pagura, D.W. Mulvin, M.E. Cowen and M.R. Johnston. Time-related effects of enzymatic disaggregation on model human lung carcinomas. Cytometry 19:1995, 146-153.

18. M. Fujita, K.R. Shroyer, N.E. Markham, M. Inoue, S. Iwamoto, S. Kyo and T. Enomoto. Association of human papillomavirus with malignant and premalignant lesions of the uterine endometrium. Hum. Pathol. 26:1995, 650-658.

19. T. Marks, K.R. Shroyer, N. Markham and R.S. Gibbs. Correlation of HPV with histopathologic changes of vulvodynia. J. Soc. Gynecol. Invest. 2:1995, 57-63.

20. T. Doherty, J. Connell, J. Stoerker, A.L. Shroyer and K.R. Shroyer. Analysis of clonality by polymerase chain reaction for phosphoglycerate kinase-1. Heteroduplex generator. Diag. Mol. Pathol. 4:1995, 182-190.

21. K.R. Shroyer, C. Brookes, N.E. Markham, and A.L. Shroyer. Detection of human papillomavirus in anorectal squamous cell carcinoma: Correlation with basaloid pattern of differentiation. Am. J. Clin. Pathol. 104:1995, 299-305.

22. S. Lewallen, R.B. Keyser, K.R. Shroyer and G. Liomba. Aggressive conjunctival squamous cell carcinoma in three young Africans. Arch. Opthalmol. 114:1996, 215-8.

23. M. Fujita, T. Enomoto, M. Inoue, Y. Okudaira, and K.R. Shroyer. Application of clonal analysis: Differential diagnosis for synchronous primary ovarian and endometrial cancers and metastatic cancer. Am. J. Clin. Pathol. 105:1996, 350-359.

24. T.J. Bohlmeyer and K.R. Shroyer. Endometriosis of the urinary bladder; a case report with cytologic findings and differentiation from transitional cell carcinoma. Letter to the Editors, Acta Cytologica 40:1996, 382-384.

25. G.W. Davila and K.R. Shroyer. Topical 5-fluorouracil in the treatment of cervical human papillomavirus infection. Gynecologic and Obstetric Investigation. 41:1996, 275-277.

26. J.T. Allen-Davis, P. Russ, F.M. Karrer, K.R.Shroyer, S. Ruyle, and L.F. Odom. Cavernous lymphangioma presenting as a vaginal discharge in a six-year-old female: A case report. J. Pediatr. Adolesc. Gynecol. 9:1996, 31-34.

27. M.O. Liranzo, L. Golitz and K.R. Shroyer. Detection of HPV DNA in cutaneous squamous cell carcinomas of a patient with mycosis fungoides: Report of a case. J. Cutaneous Pathol. 24:1997, 47-50.

28. S. Nawaz, T. Hashizumi, N.E. Markham, A.L. Shroyer, and K.R. Shroyer. Telomerase expression in human breast cancer with and without lymph node metastases. Am. J. Clin. Pathol. 107:1997, 542-547.

29. B.K. Kleinschmidt-DeMasters, N. Markham, K.O. Lillehei, and K.R. Shroyer. Differential telomerase expression in human primary intracranial tumors. Am. J. Clin. Pathol. 107:1997, 548-554.

30. D.R. Lucas, K.R. Shroyer, P.J. McCarthy, N.E. Markham, M. Fujita and T.E. Enomoto. Desmoid tumor is a clonal cellular proliferation: PCR amplification of HUMARA for analysis of patterns of X-chromosome inactivation.. Am. J. Surg. Pathol. 21:1997, 306-311.

31. K.R. Shroyer, J.K. Stephens, S.G. Silverberg, N. Markham, A.L. Shroyer, M. Wilson, and T. Enomoto. Analysis of telomerase expression in normal endometrium, endometrioid hyperplasia, and endometrial adenocarcinoma. Int. J. Gynecol. Pathol. 16:1997, 225-32.

32. B. Haugen, S. Nawaz, N. Markham, T. Hashizumi A.L. Shroyer, B. Werness, and K.R. Shroyer. Telomerase activity in benign and malignant thyroid tumors. Thyroid 7:1997, 337-342.

33. T. Enomoto, T. Haba, M. Fujita, T. Hamada, K. Wakasa, Y. Murato, and K.R. Shroyer. Clonal analysis of high grade squamous intraepithelial lesion of cervix. Int. J. Cancer 73:1997, 339-342.

34. H. Wada, T. Enomoto, M. Fujita, K. Yoshino, R. Nakashima, T. Haba, K. Wakasa, K.R. Shroyer, M. Tsujimoto, T. Hongyo, T. Nomura, Y. Murata. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res.57:1997, 5379-85.

35. K.R. Shroyer, C. Thompson, T. Enomoto, J. Eskens, A.L. Shroyer, and J.A. McGregor. Telomerase expression in normal epithelium, dysplasia and squamous cell carcinoma of uterine cervix. Am. J. Clin. Pathol. 109:1998, 153-62.

36. T. Bohlmeyer, T. Le, A.L. Shroyer, N.E. Markham and K.R. Shroyer. Detection of HPV in squamous cell carcinomas of the lung by polymerase chain reaction. Am. J. Resp. Cell and Molec Biol. 18:1998, 265-69.

37. V.J. Cunningham, N. Markham, A.L. Shroyer, and K.R. Shroyer. Detection of Telomerase Expression in Fine Needle Aspirations and Fluids. Diagn. Cytopathol. 18:1998, 1-6.

38. S-D Lee, K.R. Shroyer, N.E. Markham, C.D. Cool, N.F. Voelkel, R.M. Tuder. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J. Clin. Invest. 101:1998, 927-34.

39. B.K. Kleinschmidt-DeMasters, T.L. Hashizumi, C-I Sze, K.O. Lillehei, A.L. Shroyer, and K.R. Shroyer. Telomerase expression shows differences across multiple regions of oligodendrogliomas versus high grade astrocytomas but shows correlation with Mib-1 labeling. J. Clin. Path. 51:1998, 284-93.

40. P. Zvejnieks, S. Tellschow, E. Gudlaugsson, N.E. Markham, and K.R. Shroyer. Amelogenin dosage compensation in carcinoma of colon, lung, liver, and kidney is not a marker of clonality in males. Molecular and Cellular Probes. 12:1998, 185-190.

41. H.Wada, T. Enomoto, M. Tsujimoto, T. Nomura, Y. Murata, and K.R. Shroyer. Carcinosarcoma of the breast: Molecular-biologic study for analysis of histogenesis. Human Pathol. 29:1998, 1324-1328.

42. R.M. Tuder, Z. Radisavljevic, K.R. Shroyer, J. Polak, and N.F. Voelkel. Monoclonal endothelial cells are present in plexiform lesions of appetite suppressant-induced pulmonary hypertension. Am. J. Resp and Critical Care Med. 158:1998, 1999-2001.

43. B.K. Kleinschmidt-DeMasters, A.L. Shroyer, T.L. Hashizumi, L.C. Evans, N. Markham, G. Kindt, and K.R. Shroyer. Telomerase levels in human metastatic brain tumors show four-fold logarithmic variability but no correlation with tumor type or interval to patient demise. J. Neurol. Sci. 161:1998, 116-123.

44. B.K. Kleinschmidt-DeMasters, L.C. Evans, M.A. Bitter, A.L. Shroyer, and K.R. Shroyer. Telomerase expression in cerebrospinal fluid specimens as an adjunct to cytologic diagnosis. J. Neurol. Sci. 161:1998, 124-134.

45. C. Poremba, K.R. Shroyer, M. Frost, R. Diallo, F. Fogt, K-L. Schäfer, H. Bürger, W. Böcker, A. Laurie Shroyer, and B. Dockhorn-Dworniczak. Telomerase is a highly sensitive and specific marker in fine-needle aspirates of breast lesions. J. Clin. Oncol. 17:1999, 2020-2026.

46. R.O. Greer, G. Hoernig and K.R. Shroyer. Telomerase expression in precancerous oral verrucous hyperplasia. Int. J. Oral Biol. 24:1999, 63-67.

47. H. Wada, T. Enomoto, K. Yoshino, K. Ozaki, H. Kurachi, T. Nomura, Y. Murata, N. Kim, S. Weirnrich, D. Lopez-Uribe, and K.R. Shroyer. Immunohistochemical localization of telomerase hTERT protein and analysis of clonality in multifocal vulvar intraepithelial neoplasia. Am. J. Clin. Pathol. 114:2000, 371-79.

48. B.K. Kleinschmidt-DeMasters, L.C. Evans, J.B. Bobak, D. Lopez-Uribe, D. Hooper, A.L. Shroyer, and K.R. Shroyer. Quantitative telomerase expression in glioblastomas shows down-regulation with therapy but no correlation with patient outcome. Human Pathol. 31:2000, 905-12.

49. M. Frost, J. Bobak, R, Gianani, N. Kim, S. Weinrich, D.C. Spaulding, L.G. Cass, L.C. Thompson, T. Enomoto, D. Lopez-Uribe, and K.R. Shroyer. Localization of telomerase hTERT protein and hTR in benign mucosa, dysplasia, and squamous cell carcinoma of cervix. Amer. J. Clin. Path. 114:2000, 726-734.

50. C.I. Suh, T. Shananfelt, D.J. May, K.R. Shroyer, J. Bobak, E.D. Crawford, G.J. Miller, N. Markham, L.M. Glode. Testing of ejaculate for telomerase activity and GSTP1 promoter methylation as screening tests for prostate cancer. Molecular and Cellular Probes 14:2000, 211-17.

51. R. Gianani, E. Jarboe, M. Frost, J. Bobak, R. Lehner, D. Orlicky, and K.R. Shroyer. Expression of survivin in normal, hyperplastic and neoplastic colonic mucosa. Human Pathol. 32:2001, 119-126.

52. R. Lehner, J. Bobak, R. Gianani, N. Kim, S. Weinrich, E. Lea-Chou, J.A. McGregor, and K.R. Shroyer. Localization of telomerase hTERT protein and survivin in human placenta: Correlation with placental development and hydatidiform molar pregnancy. Obstet. and Gynecol. 97:2001, 965-970.

53. F. Fogt, C. Poremba, K. Shibao, H. Itoh, K. Kohno, R. Zimmerman, H.G. Görtz, B. Dockhorn-Dworniczak, S.J. Urbanski, N. Alsaigh, D. Heinz, A.E. Noffsinger, and K.R. Shroyer. Expression of survivin, YB-1, and MIB-1 in sporadic adenoma and DALM lesions in ulcerative colitis. Appl. Immunohistochem. Molec. Morphol. 9:2001, 143-9.

54. A. Hong, J.E. Barrera, A.D. Meyers, K.R. Shroyer, and M. Varella-Garcia. Chromosomal aneuploidy precedes morphological changes and supports multifocality in head and neck lesions. Laryngoscope 111: 2001, 1853-58.

55. R. Lehner, E. Jarboe, R. Gianani, S. Lucia, J.A. McGregor, A.L. Shroyer, and K.R. Shroyer. Localization of inhibitor of apoptosis protein-survivin in normal transitional cell epithelium and in carcinoma. Appl. Immunohistochem. Molec. Morphol. 10:2002, 134-138.

56. R. Lehner, T. Enomoto, J.A. McGregor, A.L. Shroyer, and K.R. Shroyer. Quantitative analysis of telomerase hTERT mRNA and telomerase activity in endometrioid adenocarcinoma and in normal endometrium. Gynecol. Oncol. 84: 2002, 120-25.

57. R. Lehner, T. Enomoto, J.A. McGregor, A.L. Shroyer, B.R. Haugen, U. Pugazhenthi, and K.R. Shroyer. Correlation of survivin mRNA detection with histologic diagnosis in normal endometrium and endometrial carcinoma. Acta Obstetricia et Gynecologica Scandinavica 81: 2002, 162-7.

58. M. Frost, E.A. Jarboe, R. Gianani, L.C. Thompson, T. Enomoto, D. Uribe-Lopez, and K.R. Shroyer. Immunohistochemical localization of survivin in benign cervical mucosa, cervical dysplasia, and invasive squamous cell carcinoma. Am. J. Clin. Path. 117: 2002, 738-44.

59. L. Bonds, P. Baker, C.J. Gupp, and K.R. Shroyer. Analysis of Cdc6 expression in cervical neoplasia and carcinoma. Arch. Path. Lab. Med. 126:2002, 1163-68.

60. T. Enomoto, H. Sun, K.R. Shroyer, K. Ozaki, M. Fujita, C. Kuragaki, Y. Ueda, R. Nakashima, G. Ueda, Y. Murata. Analysis of clonality and mutations of PTEN and the K-ras genes in endometrial hyperplasia. Diag Molec Path. 11:2002, 204-11.

61. K. Trieb, R. Lehner, T. Stulnig, I. Sulzbacher, and K.R. Shroyer. Survivin expression in human osteosarcoma is a marker for survival. Eur. J. Surg. Oncol. 29:2003, 379-82.

62. B.K. Kleinschmidt-DeMasters, D. Heinz, P.J. McCarthy, J.B. Bobak, K.O. Lillehei, and K.R. Shroyer. Survivin in glioblastomas: protein and mRNA expression and comparison with telomerase levels. Arch Pathol Lab Med. 127:2003, 826-33.

63. J.E. Barrera, M. Miller, S. Said, B. Jafek, J. Campana, and K.R. Shroyer. Detection of micrometastasis using immunohistochemistry of pancytokeratin in neck dissection specimens from patients with head and neck squamous cell cancer. Laryngoscope 113:2003, 892-6.

64. S. Prindiville, T. Byers, F.R. Hirsch, W.A. Franklin, Y.E. Miller, K.O. Vu, H.J. Wolf, A.E. Baron, K.R. Shroyer, C Zeng, T.C. Kennedy, and P.A. Bunn. Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. Cancer Epidem., Biomarkers, Prevention. 12:2003, 987-993.

65. Y. Ueda, T. Enomoto, T. Miyatake, K. Ozaki, T. Yoshizaki, H. Kanao, Y. Ueno, R. Nakashima, K.R. Shroyer, Y. Murata. Monoclonal expansion triggered by integration of high-risk type HPVs is an initial step for cervical carcinogenesis. Laboratory Investigation, 83:2003, 1517-27.

66. A.K. Tyagi, C. Agarwal, R.P. Singh, K.R. Shroyer, L. M. Glode and R. Agarwal. Silibinin Down-regulates Survivin Protein and mRNA Expression and Causes Caspases Activation and Apoptosis in Human Bladder Transitional-cell Papilloma RT4 Cells. Biochem. Biophys. Res. Comm. 312:2003, 1178-84.

67. E.A. Jarboe, L.C. Thompson, D. Heinz, J.A. McGregor, and K.R Shroyer. Telomerase and HPV as Diagnostic Adjuncts for Cervical Dysplasia and Carcinoma. Human Pathology, 35:2004, 396-402.

68. B. Tringler, R. Lehner, A.L. Shroyer, and K.R. Shroyer. Immunohistochemical localization of survivin in serous tumors of the ovary. Applied Immunohistochem. Molec. Morphol. 12:2004, 40-43.

69. B. Tringler, C.J. Gup, and K.R. Shroyer. Correlation between p16 and pRb expression in cervical squamous and glandular neoplasia. Human Pathology, 35:2004, 689-696. (One of Human Pathology’s top 10 cited articles in 2009).

70. K. Weber, K.R. Shroyer, D. Heinz, S. Nawaz, S. Said, and B. Haugen. The utility of a combination of galectin-3 and thyroid peroxidase in the molecular diagnosis of thyroid nodules. Am. J. Clin. Pathol. 122: 2004, 524-31.

71. Y. Ueda, T. Enomoto, T. Miyatake T, K.R. Shroyer, T. Yoshizaki, H. Kanao, Y. Ueno, H. Sun, R. Nakashima, K. Yoshino, T. Kimura, T. Haba, K. Wasaka, and Y. Murata. Analysis of clonality and HPV infection in benign, hyperplastic, premalignant, and malignant lesions of vulvar mucosa. Am. J. Clin. Pathol. 122:2004, 266-77.

72. T.C. Kennedy, W.A. Franklin, S.A. Prindiville, R. Cook, E.C. Dempsey, R.L. Keith, F.R. Hirsch, T.A. Merrick, K.R. Shroyer, T.L. Petty, T. Byers, P.A. Bunn, Y.E. Miller. High Prevalence of Endobronchial Malignancy in High-Risk Patients with Moderate Dysplasia in Sputum. Chest 125:2004, 109S.

73. M. Singh, M.J. Bleile, A.L. Shroyer, D. Heinz, E.A. Jarboe, and K.R. Shroyer. Analysis of survivin expression in a spectrum of benign to malignant lesions of the breast. Appl. Immunohistochem. Molec. Morphol. 12: 2004, 296-304.

74. B. Tringler, S. Zhuo, G. Pilkington, K.C. Torkko, M. Singh, M.S. Lucia, D.E. Heinz, J. Papkoff and K.R. Shroyer. B7-H4 is highly expressed in ductal and lobular breast cancer. Clinical Cancer Research. 11: 2005, 1842-8.

75. T.C. Kennedy, W.A. Franklin, S.A. Prindiville, R. Cook, E.C. Dempsey, R.L. Keith, F.R. Hirsch, T.A. Merrick, K.R. Shroyer, T.L. Petty, T. Byers, P.A. Bunn, Y.E. Miller. High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia. Lung Cancer 49:2005, 187-91.

76. B. Tringler, W. Liu, L. Corral, K.C. Torkko, T. Enomoto, S. Davidson, M.S. Lucia, D.E. Heinz, K.R. Shroyer, B7-H4 overexpression in ovarian carcinoma. Gynecologic Oncology 100:2006, 44-52. (Abstracted in Yearbook of Pathology and Laboratory Medicine, 2006, Mosby.)

77. J. Wilman, L. Golitz, and K.R. Shroyer. Correlation of p16 and pRb expression with HPV detection in Bowens disease. J. Cutaneous Pathol. 33:2006, 629-33.

78. N.S. Spoelstra, N.G. Manning, Y. Higashi, D. Darling, M. Singh, K.R. Shroyer, R.R. Broaddus, K.B. Horwitz, J.K. Richer. The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res 66:2006, 3893-3902.

79. R. Diallo R.,Rody A., Schaefer K.L., Kissler S., Karn T., Geddert H., Engels K.,., Gabbert H.E., Kaufmann M., Jackisch C., Shroyer K.R., Poremba C. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu. Human Pathol. 37:2006, 205-211.

80. L.M. Brown, S.M. Helmke, S.W. Hunsucker, R.T. Netea-Maier, S.A. Chiang, D.E. Heinz, K.R. Shroyer, M.W. Duncan, B.R. Haugen. Quantitative and Qualitative Differences in Protein Expression Between Papillary Thyroid Carcinoma and Normal Thyroid Tissue. Molec Carcinogen. 45:2006, 613-26.

81. J.M. Owens, K.R. Shroyer, T.T. Kingdom. Expression of cyclooxygenase and lipoxygenase enzymes in nasal polyps of aspirin-sensitive and aspirin-tolerant patients. Arch Otolaryngol Head Neck Surg. 132:2006, 579-87.

82. J.H Willman, D. Heinz D, L.E. Golitz LE, K.R. Shroyer. Correlation of p16 and pRb expression with HPV detection in Bowen's disease. J Cutan Pathol. 2006, 33:629-33.

83. T. Miyatake, T. Enomoto, Y. Ueda, K.R. Shroyer, T. Yoshizaki, H. Kanao. Ueno, H. Sun, R. Nakashima, K. Yoshino, T. Kimura, T. Haba, K. Wakasa, Y. Murata. Clonality Analysis and HPV Infection in Squamous Metaplasia and Atypical Immature Metaplasia of Uterine Cervix: Is Atypical Immature Metaplasia a Precursor to CIN 3? Int J Gynecol Pathol. 26:2007, 180-7.

84. N.S. Awadallah, D. Dehn, R.J. Shah, Y.K. Chen, D. Ross, J.S. Bentz, K.R. Shroyer. NQO1 Expression in Pancreatic Cancer and its Potential use as a Biomarker. Appl Immunohistochem Mol Morphol. 2008:24-31.

85. K.R. Shroyer, D. Heinz, Petra Homer, and M. Singh. Validation of a novel immunocytochemical assay for topoisomerase II alpha and minichromosome maintenance protein 2 expression in cervical cytology. Cancer Cytopathology. 108:2006, 324-30.

86. R.O. Greer, Jr., S.M. Said, K.R. Shroyer, M. Varella-Garcia, and S.A. Weed. Overexpression of Cyclin D1 and Cortactin is Primarily Independent of Gene Amplification in Salivary Gland Adenoid Cystic Carcinoma. Oral Oncol. 2007:735-41.

87. T. Miyatake, B. Tringler, D. Dehn, A. Swisher, W. Liu, S. Lee, L. Corral, J. Papkoff, T. Enomoto, K.C. Torkko, K.R. Shroyer. B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid carcinomas and is inversely correlated with tumor T cell infiltration. Gynecologic Oncology. 106: 2007, 119-27.

88. K.C. Mugler, M. Singh, B. Tringler, J. Papkoff, W. Lui, and K.R. Shroyer. B7-H4 Expression in a Range of Breast Pathology: Correlation With Tumor T-cell Infiltration.

Applied Immunohistochemistry and Molecular Morphology. 15:2007, 363-370. 89. N.S. Awadallah, K.R. Shroyer, D.A. Langer, K.C. Torkko, Y.K. Chen, J.S. Bentz, J. Papkoff, W. Liu, R.J.

Shah, Detection of B7-H4 (DD-O110) and p53 in pancreatic cancer: potential roles as cytologic diagnostic adjuncts, Pancreas. 36:2008, 200-6.

90. R.O. Greer, A. Meyers, S.M. Said, K.R. Shroyer. Is p16(INK4a) protein expression in oral ST lesions a reliable precancerous marker? Int J Oral Maxillofac Surg. 2008:840-6.

91. Ling J., Wiederkher U., Cabiness, S., Shroyer K.R., Robinson J. Application of flow cytometry for biomarker-based cervical cancer cells identification. Cancer Cytopathology 36:2008, 76-84.

92. E.M. Reno, J.M. Haugen, I.K. Dimitrova, T.A. Jackson, K.R. Shroyer, A.P. Bradford. Analysis of protein kinase C delta (PKCδ) in endometrial tumors. Hum Pathol. 2008:21-9.

93. J.M. Owens, K.R. Shroyer, T.T. Kingdom. Expression of cyclooxygenase and lipoxygenase enzymes in sinonasal mucosa of cystic fibrosis patients. Arch. Otolaryngol Head Neck Surg. 134: 2008, 825-31.

94. T. Byers, H. Wolf, W.A. Franklin, S. Braudrick, D. Merrick, K.R. Shroyer, F.R. Hirsch, C. Zeng, A.E. Barón, P.A. Bunn, Y.E. Miller, T.C. Kennedy. Sputum Cytologic atypia predicts incident lung cancer: Defining a latency and histologic specificity. Cancer Epidemiol Biomarkers Prev 17: 2008, 158-62.

95. M. Singh, N.S. Spoelstra, A. Jean, E. Howe, K.C. Torkko, H.R. Clark, D.S. Darling, K.R. Shroyer, K.B. Horwitz, R.R. Broaddus, J.K. Richer. ZEB1 expression in type I versus type II endometrial cancers: a marker of aggressive disease. Mod Pathol. 2008 21:912-23.

96. J.E. Barrera, K.R. Shroyer, S. Said, G. Hoernig, R. Melrose, P.D. Freedman, T.A. Wright, R.O. Greer. Estrogen and progesterone receptor and p53 gene expression in adenoid cystic carcinoma. Head and Neck Pathol. 2008 2:13-8.

97. B.A. Larsen, A.J. Barker, R. Shandas, N. Serkova, K.R. Shroyer, Conrad R. Stoldt. Controlled aggregation of superparamagnetic iron oxide nanoparticles for the development of molecular magnetic resonance imaging probes. Nanotechnology 2008 19:1-7

98. E.U. Yee, R.J. Zaino, Kathleen C. Torkko, K.R. Shroyer. B7-H4 expression in Brenner tumors, a descriptive and comparative study. Histopathology. 2010 56:652-4.

99. P.S. MacLean, E.D. Giles, G.C. Johnson, S.M. McDaniel, B.K. Fleming-Elder, K.A. Gilman, A.G. Andrianakos, M.R. Jackman, K.R. Shroyer, P.J. Schedin. A surprising link between the energetics of weight gain and mammary tumor progression in a model of postmenopausal obesity. Obesity, 2010 18:696-703.

100. Y.-K. Luu, E. Ozcivici, E.Capilla, B. Adler, E. Chan, K.R. Shroyer, J. Rubin, S. Judex, J. Pessin, C.T. Rubin. Development of Diet Induced Fatty Liver Disease in the Aging Mouse is Suppressed by Brief Daily Exposure to Low Magnitude Mechanical Signals. Int. J. Obesity, 2010 34:401-5.

101. E.F. Redente, L.D. Dwyer-Nield, K. Raina, P.L. Rice, D.T. Merrick, W. Pao, J.A. Whitsett, R. Agarwal, K.R. Shroyer, A.M. Malkinson. Tumor Progression Stage and Anatomical Site Regulate Tumor- Associated Macrophage and Bone Marrow-Derived Monocyte Activation. Am J Pathol. 2010 176:2972-85.

102. P. Samarawardana, D.L. Dehn, M. Singh, D. Franquemont, C. Thompson, L. Gaido, K.C. Torkko, P. Homer, S. Burke, M.A. Titmus, V. Nayi, K.R. Shroyer. p16INK4a is Superior to High Risk HPV Testing in Cervical Cytology for Prediction of Underlying High Grade Dysplasia. Cancer Cytopathology, 2010 25;118:146-56.

103. Botchkina GI, Zuniga ES, Das M, Wang Y, Wang H, Zhu S, Savitt AG, Rowehl RA, Leyfman Y, Ju J, Shroyer K, Ojima I. New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells. Mol Cancer. 2010 14:192.

104. P.K. Avti, H. Song, S. Hu, C. Favazza, A.G. Mikos, J.A. Jansen, K.R. Shroyer, L.V. Wang, B. Sitharaman. Detection, mapping and quantification of single walled carbon nanotubes in histological specimens by Photoacoustic Microscopy. PLoS ONE 2012 7(4): e35064.

105. J. Du, C. Leonhard-Melief, H. Takeuchi, K.R. Shroyer, M. Dlugosz, R.S. Haltiwanger, B.C. Holdener. Protein O-fucosyltransferase 2 (Pofut2) is Required to Restrict Epithelial to Mesenchymal Transition (EMT) During Mouse Gastrulation. Dev. Biol. 2010 346:25-38.

106. H.G. Ren, W.C. Waltzer, K.R. Shroyer, Y.T. Pan. Enhancing the detection of carcinoma in situ of the urinary bladder by 3D optical coherence tomography. J. Urology, 2010, 184(4):1499-506.

107. J. Keller, K.R. Shroyer, H. Zhao, L.M. Dong, M.J. Hayman, E.L. Chan Combination of phosphorylated and truncated EGFR predicts advanced stage in head and neck cancer. Cancer Investigation, 2010, 28:1054-62.

108. M. Singh, K. Mugler, D.W. Hailoo, S. Burke, B. Nemesure, K. Torkko, K.R Shroyer. Differential expression of transferrin receptor (TfR) in a spectrum of normal to malignant breast tissues: implications for in situ and invasive carcinoma. Appl Immunohistochem Mol Morphol. 2011, 19:417-23.

109. Y. Chen, G. Guo, S. Guo, S. Shimoda, K.R. Shroyer, Y. Tang, Y. Wu.. Intracellular B7-H4 Suppresses Bile Duct Epithelial Cell Apoptosis in Human Primary Biliary Cirrhosis. Inflammation. 2011 34:688-97.

110. S. Hwang and K.R. Shroyer. Biomarkers of Cervical Dysplasia and Carcinoma. Biomarkers in Medicine J Oncol. 2012;2012:507286. Epub 2011 Oct 29.

111. P.Samarawardana, M. Singh, K.R. Shroyer. Dual Stain Immunohistochemical Localization of p16INK4a and Ki-67: A Synergistic Approach to Identify Clinically Significant Cervical Mucosal Lesions. Appl Immunohistochem Mol Morphol. 2011, 19:514-8.

112. P.K. Premsrirut, L.E. Dow, S.Y. Kim, M. Camiolo, C.D. Malone, C. Miething, C. Scuoppo, J. Zuber, R.A. Dickins, S.C. Kogan, K.R. Shroyer, R. Sordella, G.J. Hannon, S.W. Lowe. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 145:145-58 (2011).

113. M. Singh, D. Mockler, A. Akalin, S. Burke, A.L. Shroyer, and K.R. Shroyer. Dual localization of p16INK4a and Ki-67 detects high grade cervical intraepithelial neoplasia and cancer. Cancer Cytopathol 120:26-34 (2012).

114. H. Zhai, S. Acharya, I. Gravanis, S. Mehmood, R.J. Seidman, K.R. Shroyer, K.A. Hajjar, S.E. Tsirka. Annexin A2 Promotes Tumor Progression in Glioma Cells. J Neuroscience 31:14346-60 (2011).

115. H. Ren, W.C. Waltzer, K.R. Shroyer, Y. Pan. Early Detection of Carcinoma in situ of the Bladder: A Comparative Study of White Light Cystoscopy, Narrow Band Imaging, 5-ALA Fluorescence Cystoscopy and 3D Optical Coherence Tomography. J Urology 2012 187:1063-70.

116. G. Pagnotti, B.J. Adler, D.E. Green, M.E. Chan, K.R. Shroyer, W.G. Beamer, J. Rubin, C.T. Rubin. Low magnitude mechanical signals mitigate osteopenia without compromising longevity in an aged murine model of spontaneous granulosa cell ovarian cancer. Bone 2012 51:570-7.

117. P. Georgakopoulos, S. Mehmood, A. Akalin, K.R. Shroyer. Immunohistochemical Localization of HE4 in Benign, Borderline, and Malignant Lesions of the Ovary. Int J Gynecol Pathol, 2012;31:517–523.

118. M. Karaayvza, C. Zhang, S. Liang, K.R. Shroyer, J. Ju . Prognostic Significance of miR-205 in Endometrial Cancer. PLOS ONE. 2012;7(4):e35158.

119. A. Heimann, G Maini, S Hwang, K.R. Shroyer, M. Singh. Use of telecytology for the immediate assessment of CT guided and endoscopic FNA cytology: Diagnostic accuracy, advantages, and pitfalls. Diagn Cytopathol. 2012 40:575-81.

120. M. Mathison, R. Gersch, A. Nasser, M. Korman, M. Fourman, N. Hackett, K.R. Shroyer, J. Yang, Y. Ma, R. Crystal, T.K. Rosengart, In Vivo Cardiac Cellular Reprogramming Efficacy is Enhanced by Angiogenic Preconditioning of the Infarcted Myocardium with Vascular Endothelial Growth Factor. J Am Heart Assoc. 2012 e005652.

121. E.S. Zuniga, R. Park, R.H. Rowehl, R. Bhalla, A.R. Ivanov, A.B. Bialkowska, F. Johnson, L.M. Golub, Y. Zhang, K.R. Shroyer, I. Ojima, G.I. Botchkina. Prostate cancer stem cell-targeted efficacy of a new generation taxoid, SBT-1214 and novel polyenolic zincbinding curcuminoid, CMC2.24 PLoS One. 2013 e69884

122. J. Keller, A.S. Nimnual, K.R. Shroyer, C. Joy, I. Ischenko, C.S. Chandler, L.M. Dong, M.J. Hayman, E.L. Chan. Ron kinase synergies with EGFR to confer adverse features in head and neck squamous cell carcinoma. Br J Cancer. 2013; 109 (2):482-92

123. M. Katz, M.E. Parrish, E. Li, Y. Zhang, W.Zhu, K.R. Shroyer, R. Bergamaschi, J.L. Williams. The Effect of Race/Ethnicity on the Age of Colon Cancer Diagnosis. J Health Disparities Res Practice. 2013; 6: 62-69.

124. S. Kanakia, J. Touissant, S.M. Chowdhury, G. Lalwani, T. Tembulkar, T. Button, K.R. Shroyer , W. Moore, B. Sitharaman. Physicochemical Characterization of A Novel Graphene-Based Magnetic Resonance Imaging Contrast Agent. Int J Nanomedicine 2013; 8: 2821–2833.

125. J. Keller, A. Nimnual, K.R.Shroyer, C. Joy, I. Ischenko, C. Chandler, L.M. Dong, M. Hayman, E. Chan. Ron tyrosine kinase receptor synergies with EGFR to confer adverse features in head and neck squamous cell carcinoma. Br J Cancer (2013), 1–11.

126. A.V. Taibi, J.K. Lighthouse, R.C. Grady, K.R. Shroyer, B.C. Holdener. Development of a conditional Mesd allele for functional analysis of the low-density lipoprotein receptor-related family in defined tissues. PLOS ONE (2013) 8(10):e75782.

127. M.O. Nandan, A.M. Ghaleb, Y. Liu, A.B. Bialkowska, B.B. McConnell, K.R. Shroyer, V.W. Yang. Inducible Intestine-specific Deletion Of Krüppel-Like Factor 5 Is Characterized By A Regenerative Response In Adult Mouse Colon. Develop Biol 387: 191-202, 2014.

128. E. Li, P. Ji, N. Ouyang, Y. Zhang, X. Wang, D.C. Rubin, N.O. Davidson, K.R. Shroyer, S. Burke, W. Zhu, J.L. Williams. Differential Expression of miRNAs: Implications in Colon Cancer Racial Health Disparity. Int J Oncol DOI: 10.3892/ijo.2014.2469, 2014.

129. L.F. Escobar-Hoyos, J. Yang, J. Zhu, J.A.nn Cavallo, H. Zhai, S. Burke, A. Koller, E.I. Chen, K.R. Shroyer. Keratin 17 in premalignant and malignant squamous lesions of the cervix: proteomic discovery and immunohistochemical validation as a diagnostic and prognostic biomarker. Mod Pathol 27: 621-30, 2014.

130. S.M. Chowdhury, S. Kanakia, J. Touissant, M.D.Frame, A.M. Dewar, K.R. Shroyer, W. Moore, B. Sitharaman. In Vitro and In Vivo Hematological Assessment of Dextran Functionalized Graphene. Scientific Reports . Sci Rep. 2013 3:2584. doi: 10.1038/srep02584. PMID 24002570

131. G.I. Botchkina, E.S. Zuniga, R.H. Roweh, R. Park, R. Bhalla, A.B. Bialkowska, F. Johnson, L.M. Golub, Y. Zhang, I. Ojima, K.R. Shroyer. Prostate Cancer Stem Cell-Targeted Efficacy of a New-Generation Taxoid, SBT-1214 and Novel Polyenolic Zinc-Binding Curcuminoid, CMC2.24. PLOS ONE 8: 1-16. 2013. e69884

132. S. Kanakia, J. Toussaint, S. M. Chowdhury, T. Tembulkar, S. Lee, Y.-P. Jiang, R.Z. Lin, K.R. Shroyer, W. Moore, B. Sitharaman. Dose Ranging, Expanded Acute Toxicity and Safety Pharmacology Studies for Intravenously Administered Functionalized Graphene Nanoparticle Formulations. Biomaterials. 2014;35(25):7022-31. doi: 10.1016/j.biomaterials.2014 PMID 24854092

133. E. Regenbogen, M. Mo, J. Romeiser, A.L.Shroyer, L.F. Escobar-Hoyos, S. Burke, K.R. Shroyer. Keratin 17 is a prognostic biomarker oropharyngeal squamous cell carcinoma. (In press, Head and Neck)

134. N.A Evensen, C. Kuscu, Y. Li, Q. Zhang, J. Liu, E. Li, P.I. Denoya, K.R. Shroyer, J. Cao. Hypoxia-inducible-Factor-2 (HIF-2) Upregulates the Cell Migration-Inducing Protein (CEMIP/KIAA1199) in Response to Hypoxic Stress (Submitted for publication)

135. R.A. Rowehl, S. Burke, A.B. Bialkowska, D.W. Pettet III, L. Rowehl, E. Li, E. Antoniou, Y. Zhang, R. Bergamaschi, K.R. Shroyer, I. Ojima, G.I. Botchkina. Establishment of Highly Tumorigenic Human Colorectal Cancer Cell Line (CR4) with Properties of Putative Cancer Stem Cells. PLoS One. 2014 Jun 12;9(6):e99091 PMID: 24921652

136. M. Altieri, K.R. Shroyer, A. Pryor, G. Pagnotti, M.E. Chan, M. Talamini, D.A. Telem. The Association between Sleeve Gastrectomy and Histopathologic Changes Consistent with Esophagitis in a Rodent Model. Surg Obes Related Dis. doi:10.1016/j.soard.2015

137. S. Kanakia, J. Toussaint, D.M. Hoang , S.M. Chowdhury, S. Lee, K.R. Shroyer, W. Moore, Y.Z. Wadhgiri, B. Sitharaman. Safety and Efficacy of Graphene Based High Performance Magnetic Resonance Imaging Contrast Agent. Graphene Technology, 1: 17-28, 2016.

138. L. Vanner and K.R. Shroyer. Comments on HPV and lung cancer risk: a meta-analysis. J Clin Virol. 2014 Nov 20. PMID: 25466494

140. E.R. Snedecor, C. Sung, A. Moncayo, B.E. Rothstein, D.C. Mockler, M.G. Tonnesen, E.C. Jones, M. Fujita, R.A. Clark, K.R. Shroyer, J. Chen. Loss of primary cilia correlates with melanoma J Investigative Dermatology advance online publication 2015; doi: 10.1038/jid.2015.22

141. N.A Evensen, Y. Li, C.K., J. Liu, J. Cathcart, A. Banach, E. Li, J. Yang, P.I. Denoya, S. Zucker, K.R. Shroyer and J. Cao. Hypoxia Promotes Colon Cancer Dissemination Through Up-regulation of Cell Migration-Inducing Protein (CEMIP). Oncotarget online publication 2015/ Online ISSN: 1949-2553.

142. Y. Liu, E.R. Snedecor, Y.J. Choi, N. Yang, X. Zhang, Y. Xu, Y. Han, E.C. Jones, K.R. Shroyer, R.A. Clark, L. Zhang, C. Qin, J. Chen. Gorab is essential for hedgehog signaling during embryonic morphogenesis. Journal of Investigative Dermatology 2016 136:378-86. doi: 10.1016/j.jid.2015.10.067.

139. L.F. Escobar-Hoyos, R. Shah, L. Roa-Peña, N. Najafian, E. Vanner, A. Banach, E. Nielsen, R. Al-Khalil, Ali Akalin, D. Talmage, K.R. Shroyer. Keratin 17 mediates p27KIP1-nuclear export, promoting G1-phase progression and tumor growth. Cancer Research. Cancer Res. 2015 Sep 1;75(17):3650-62. PMID: 26109559

143. S. Kanakia, J. Toussaint, D.M. Hoang, S.M. Chowdhury, S. Lee, K.R. Shroyer, W. Moore, Y.Z. Wadghiri, B. Sitharaman. Towards An Advanced Graphene-Based Magnetic Resonance Imaging Contrast Agent: Sub-acute Toxicity and Efficacy Studies in Small Animals. Scientific Reports, 5: 17182-17182, 2014.

144. G. Pagnotti, B. Adler, M. Chan, K.R. Shroyer, J. Rubin, C. Rubin. Low Intensity Mechanical Signals Slow Tumor Progression and Protect Bone Quantity and Quality in a Mouse Model of Multiple Myeloma. Cancer Discovery. Bone. 90:69-79, 2016. PMID: 27262776

146. B. Sitharaman, K.R. Shroyer, J. Toussaint, S.M. Chowdhury, W. Moore, S. Mallipattu, P. Kulkarni. Graphene Based High Performance Magnetic Resonance Imaging Contrast Agent for Diagnosis and Monitoring of Renal Abnormalities. (Submitted for publication)

147. Li Y, Kuscu C, Banach A, Zhang Q, Pulkoski-Gross A, Kim D, Liu J, Roth E, Li E, Shroyer KR, Denoya P, Zhu X, Chen L, Cao J. microRNA-181a-5p Inhibits Cancer Cell Migration and Angiogenesis via Downregulation of Matrix Metalloproteinase-14. DOI: 10.1158/0008-5472. CAN-14-2875. Cancer Res; 75(13); 1-12.

148. A. Ruiz de Sabando, C. Wang, Y. He, M. Garcia-Barros, J. Kim, K.R. Shroyer, T.D. Bannister, V.W. Yang, A. Bialkowska. ML264 - a novel small molecule that efficiently inhibits the growth of colorectal cancer xenografts in mice. Molec Cancer Ther. 15:72-83, 2016, PMID 26621868

149. C. Frenkel, D. Telem, A. Pryor, M. Altieri, K.R. Shroyer, E. Regenbogen. The Effect of Sleeve Gastrectomy on Extraesophageal Reflux Disease. Surgery for Obesity and Related Diseases. Surg Obes Relat Dis 12:1263-1269, 2016. PMID 26965156.

150. L.F. Escobar-Hoyos, E.A. Vanner, S. Schechter, L. Roa-Peña, J. Wint, J. Li, S. Powers, A. Akalin, J. Bandovic and K.R. Shroyer. Value of Keratin 17 in Pancreatic Ductal Adenocarcinoma: Risk Stratification within Clinical Stage and Grade using immunohistochemical and TCGA expression analyses. (manuscript in preparation).

151. Y.Gao, E.A. Vanner, L.F. Escobar Hoyos, C. Metter, D. Coldren, T. Kurc, KR. Shroyer, J. Saltz. Nuclear 3D quantitative morphological characterization of pancreatic adenocarcinoma. (manuscript in preparation).

152. J.T. Miyauchi, D. Chen, M. Choi, J.C. Nissen, K.R. Shroyer, S. Djordevic, I.C. Zachary, D. Selwood, S.E. Tsirka. Ablation of Neuropilin 1 from glioma-associated microglia. Oncotarget. 7: 98-1-14, 2016. PMID 26755653.

153. J. Rao, L. Escobar-Hoyos, K.R. Shroyer. Unmet clinical needs in cervical cancer screening. MLO Med Lab Obs. 2016 48:8-15. PMID: 26887092.

154. M. Altieri, A. Pryor, G. Pagnotti, M. Talamini, K.R. Shroyer, A. Corthals, D. Telem. The Association between Sleeve Gastrectomy and Histopathologic Changes Consistent with Esophagitis in a Rodent Model. Surg Endoscop (In press) PMID: 27924393

155. S. Kanakia, J. Toussaint, P. Kukarni, S. Lee, S.M. Chowdhury, S. Khan, S.K. Mallipattu, K.R. Shroyer, W. Moore, B. Sitharaman. Safety and Efficacy of A High Performance Graphene-Based Magnetic Resonance Imaging Contrast Agent for Renal Abnormalities. Graphene Technol. 2016 1:17-28. PMID: 28261636.

156. F. A. Dilmanian, J. Stavro, N. Fatemi, S. Sobotka, J. Davis, K. Spuhler, Z. Zhong, C.R. Messina, N.R. Desnoyers, J. Park, M. Korman, S. Burke, M. Morales, S. Niazi, M. Som, A.L. Jenkins III, K.R. Shroyer. Repeated x-ray-microbeam irradiation of the rat spinal cord contusion injury produces hind-leg functional recovery. (Submitted to the Journal of Neurosurgery: Spine).

157. W. Moore, P. Bhattacharji, L.F. Escobar-Hoyos, K. Yaddanapuddi, K.R. Shroyer. Keratin 17 is an Imaging and Prognostic Biomarker in Lung Cancers (submitted for publication).

158. N. Yang, E. Lai-Han Leung, C. Liu, L. Li, T. Eguether, X. Jun Yao, E. Jones, D. Norris, A. Liu, R. Clark, D. Roop, G. Pazour, K R. Shroyer, J. Chen. INTU is essential for oncogenic Hh signaling through regulating primary cilia formation in basal cell carcinoma (BCC). Oncogene (in press)

159. R.D. Merkin, E.A. Vanner, J.L. Romeiser, A.L. Shroyer, L.F. Escobar-Hoyos, J. Li, R.S. Powers, S. Burke, K.R. Shroyer. Keratin 17 is Overexpressed and Predicts Poor Survival in ER- /HER2- Breast Cancer. Human Pathol. 62:23-32, 2017. PMID: 27816721

160. D. Mockler, L. Escobar-Hoyos, A. Akalin, J. Romeiser, A.L. Shroyer. K.R. Shroyer. Keratin 17 is a prognostic biomarker in endocervical glandular neoplasia. Am J Clin Pathol. 148:264-273 2017.

161. Y.J. Choi, C. Laclef, N. Yang, J. Lewis, X. Mao, Z. Wang, L. Li, E.R. Snedecor, K.-I. Takemaru, J. Yu, S. Schneider-Maunoury, K.R. Shroyer, Y.A. Hannun, P.J. Koch, R.A. Clark, A.S. Payne, A.P. Kowalczyk, J. Chen. RPGRIP1L participates in epidermal keratinocyte adhesion through regulating desmoglein endocytosis (submitted for publication)

162. M. Wu, K.R. Shroyer. Strategies for Building a Successful Ultrasound Guided FNA Practice in Department of Pathology - Experience at a University Hospital. Diag Cytopathol. Diagn Cytopathol. 2017 45:878-882. PMID: 28699306

163. Y. Hannun, M. Wada, D. Canals, M. Adada, N. Coant, M. Salama, K. Helke, J.S. Arthur, K.R. Shroyer, K. Kitatani, L. Obeid. P38 delta MAPK promotes breast cancer progression and lung metastasis by enhancing cell proliferation and cell detachment. (In press, Oncogene)

164. J. Paredes, P. Ji, J.F. LaComb, K.R. Shroyer, L. Martello-Rooney, J.L. Williams. Establishment of Three Novel Cell Lines Derived From African American Colorectal Carcinomas: A Unique Tool for the Study of Racial Health Disparity. Int. J Oncol (In press)

165. G.M. Pagnotti, R.M. Atkinson, J.L. Romeiser, M.B. Korman, A. Akalin, K.R. Shroyer. B7-H4 is Inversely Correlated with T Cell Infiltration in Clear Cell but not Serous or Endometrioid Ovarian Cancer. Appl. Immunohist. Molec. Morph. 2017 PMID: 29189263

166. D. Lozeau, E. Snedecor, Y. Liu, W. Hou, E. Vanner, E. Batista, Y.J. Choi, N. Yang, H. Xu, W. Liang, G. Ma, P. Chen, X. Chen, C. Qin, E.L.H. Leung, T. Huston, L. Lynn, A. Korzenko, E.C. Jones, M.G. Tonneson, R.A. Clark, J.B. Lee, K.R. Shroyer, J. Chen. Diminished primary cilia distinguish melanoma from melanocytic lesions with atypia. (submitted for publication)

167. M. Gao, M. Lin, J. Park, K. Hirai1, S. Hoque, J. Vacirca, J.M. Buscaglia, G.V. Georgakis, M. Choi, K.R. Shroyer, A.R. Sasson, M. Talamini, J. n . Immune Checkpoints are Functional Therapeutic Targets on Pancreatic Cancer Cells. (In press, Ann Surg Oncol)

168. M. Gao, M. Lin, H. Thompson, K. Hirai, M. Choi, G.V. Georgakis, A.R. Sasson, J.C. Bucobo, D. Tzimas, L. D’Souza, J.M. Buscaglia, J. Davis, K.R. Shroyer, M. Rao, J. Li, R.S. Powers, J. Kim. Development of

Patient Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues. Ann Surg Oncol. 2018 25:2767-2775.MID: 30003451

169. Regenbogen E, Mo M, Romeiser J, Shroyer ALW, Escobar-Hoyos LF, Burke S, Shroyer KR. Elevated expression of keratin 17 in oropharyngeal squamous cell carcinoma is associated with decreased survival. Head Neck. 2018 40:1788-1798. PMID: 29626364

170. M. Wada , D. Canals, M. Adada, N. Coant, M.F. Salama, K.L. Helke, J.S. Arthur, K.R. Shroyer, K. Kitatani, L.M. Obeid, Y.A. Hannun. P38 delta MAPK promotes breast cancer progression and lung metastasis by enhancing cell proliferation and cell detachment. Oncogene. 2017 36:6649-6657

171. N. Yang , E. L. Leung, C. Liu, L. Li, T. Eguether, X.J. Jun Yao, E.C. Jones, D.A. Norris, A. Liu, R.A. Clark, D. Roop, G.J. Pazour, K.R. Shroyer, J. Chen. INTU is essential for oncogenic Hh signaling through regulating primary cilia formation in basal cell carcinoma. Oncogene. 2017 36:4997-5005. PMID: 28459465

172. M.S. Altieri, G. Pagnotti, A. Corthals , K.R. Shroyer, A.D. Pryor, M. Talamini, D.A. Telem. Autologous augmentation of hiatal hernia repair with filtered platelet concentrate improves tissue remodeling in a swine model. Surg Endosc. 2017 31:1591-1598. PMID: 27924393.

173. F. Bianco, G. Romano, P. Tsarkov, G. Stanojevic, K.R. Shroyer, S. Giuratrabocchetta, R. Bergamaschi. Extralevator with vs nonextralevator abdominoperineal excision for rectal cancer: the RELAPe randomized controlled trial. International Rectal Cancer Study Group. Colorectal Dis. 2017 19:148-157. PMID: 27369739

174. J. Saltz, R. Gupta, L. Hou, T. Kurc, P. Singh, V. Nguyen, D. S., K.R. Shroyer, T. Zhao, R. Batiste, J. Van Arnam, The Cancer Genome Atlas Research Network, I. Shmulevich, A.U.K. Rao, A.J. Lazar, A. Sharma, Ve´ steinn Thorsson. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Reports 2018 23, 181–193.

175. S. Babu 2, D.C. Mockler, L. Roa-Peña, A. Szygalowicz, N.W. Kim, S. Jahanfard, S.S. Gholami, R. Moffitt, J.P. Fitzgerald5, L.F. Escobar-Hoyos, K.R. Shroyer. Keratin 17 is a Sensitive and Specific Biomarker of Urothelial Neoplasia 2018 [Epub ahead of print] PMID:30443013

176. M. Gao, M. Lin, R. Moffitt, M. Salazar, J. Park, J. Vacirca, C. Huang, K.R. Shroyer, M. Choi, G. Georgakis, A. Sasson, M. Talamini, J. Kim. Direct Therapeutic Targeting of Immune Checkpoint PD-1 in Pancreatic Cancer. British J Cancer Br J Cancer. 2018 [Epub ahead of print] PMID: 30377341

177. J. Paredes, P. Ji, J.F. Lacomb, K.R. Shroyer, L.A. Martello, J.L. Williams. Establishment of three novel cell lines derived from African American patients with colorectal carcinoma: A unique tool for assessing racial health disparity. Int J Oncol. 2018 53:1516-1528. PMID: 30066857

178. Y.J. Choi, C. Laclef, N. Yang, A.A. Cervera, J. Lewis, X. Mao, L. Li, E.R. Snedecor, K.-I. Takemaru, C. Qin, S. Schneider-Maunoury, K.R. Shroyer, Y.A. Hannun, P.J. Koch, R.A. Clark, A.S. Payne, A.P. Kowalczyk, J. Chen.1 RPGRIP1L is required for stabilizing epidermal keratinocyte adhesion through regulating desmoglein endocytosis (in press).

179. Yang VW, Liu Y, Kim J, Shroyer KR, Bialkowska AB. Increased Genetic Instability and Accelerated Progression of Colitis-associated Colorectal Cancer through Intestinal Epithelium-specific Deletion of Klf4. Mol Cancer Res. 2018 [Epub ahead of print] PMID: 30108164

Book Chapters: 1. K.R. Shroyer, T. Moriuchi, T. Koji and P.K. Nakane. Use of cDNA for In Situ Hybridization. In:

Cellular, Molecular and Genetic Approaches to Immunodiagnosis and Immunotherapy (K. Kano, S. Mori, T. Sugasaki and M. Torisu, eds.), Tokyo, University of Tokyo Press, 1987, pp. 141-

154.

2. R.O. Greer, K.R. Shroyer and L. Crosby. Identification of human papillomavirus DNA in smokeless tobacco keratoses, premalignant and malignant oral lesions by PCR amplification with consensus sequence primers. In: Smokeless Tobacco or Health, an International Perspective, National Institutes of Health Monograph 2, 183-190, 1992.

3. T. Miyatake and K.R. Shroyer. Immunohistochemical validation of B7-H4 (DD-O110) as a biomarker of ovarian cancer: correlation with CA-125. In: Immunohistochemistry of in situ Hybridization of Human Carcinomas, Volume 4, pp 499-503. M.A. Hayat editor, St. Louis, MO, Graphic World Publishing Services, 2006.

4. D. Dehn and K.R. Shroyer. Screening for Molecular Markers of Cervical Papillomavirus Infection: Overview of Methods and Their Clinical Implications. In: Methods in Molecular Biology. Inflammation and Cancer: Methods and Protocols: Volume 1: Experimental Models and Practical Approaches, Editor: Serguei V. Kozlov. 511: 297-310. SpringerProtocols. (2008).

5. W.A. High and K.R. Shroyer. Bowen's Disease. In: Encyclopedia of Molecular Mechanisms of Diseases. Springer Inc. (2009) LXXXVI, 2270 p. 646 illus. In 3 volumes.

6. D.D. Dehn, A. Taylor, T.J. Fischer, D.P. Malinowski and K.R. Shroyer. Screening for molecular markers of cervical papillomavirus infection: overview of methods and their clinical implications. In: Methods in Molecular Biology, Inflammation, and Cancer, vol. 511, Humana Press, New York. Kozlov (ed.) pp. 297-310, 2009.

Invited Editorial: 1. K.R. Shroyer. Human papillomavirus and endocervical adenocarcinoma. Hum. Pathol. 24:1993, 119-

120. 2. K.R. Shroyer. Immunohistochemical markers of cell immortality. Hum. Pathol. 33: 2002, 683-85. . K.R. Shroyer, S.T. Dunn, Guest Editors. Update on Molecular Diagnostics for the Detection of Human

Papillomavirus. Journal of Clinical Virology. 45: 2009, S1. Invited Review: 1. E.A. Jarboe, K.-L. Liaw, C. Thompson, D. Heinz, P. Baker, J.A. McGregor, T. Dunn, J.E. Woods, and

K.R. Shroyer. Analysis of Telomerase as a Diagnostic Biomarker of Cervical Dysplasia and Carcinoma. Oncogene, 21:2002, 664-673.

2. J.K. Wolf, E.L. Franco, J.M. Arbeit, K.R. Shroyer, T.C. Wu, C.D. Runowicz, G. Tortolero-Luna, R. Herrero, C.P. Crum. Innovations in understanding the biology of cervical cancer. Cancer 98:2003, 2064-9.

3. Dehn D., Torkko K. and Shroyer K.R. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer Cytopathology, 111:2007, 1-14.

4. Thomison, J., Kopecki-Thomas, L, and Shroyer, K.R. Human Papillomavirus: Molecular and Cytologic/Histologic Aspects Related to Cervical Intraepithelial Neoplasia and Carcinoma. Human Pathol. 39:2008, 154-166.

5. Samarawardana P, Shroyer KR . VTCN1 (V-set domain containing T cell activation inhibitor 1). Atlas Genet Cytogenet Oncol Haematol. February 2008 . URL: http://AtlasGeneticsOncology.org/Genes/

6. J. Rao, L. Escobar-Hoyos, K.R. Shroyer. Unmet clinical needs in cervical cancer screening. Medical Lab Observ. January 2016 • Vol. 48 • No. 1

Invited Book Review:

K. R. Shroyer. In situ polymerase chain reaction and related technology. Ed. J. Gu (Book review). J. Chem. Neuroanat. 14: 1997.

Ph.D. Thesis: K.R. Shroyer. Immunohistochemical Localization of Albumin and In Situ Hybridization of Albumin

Messenger-RNA. University Microfilms International, 1983. Abstracts (2007-present): 102. R Greer, A Meyers, S Said, K.R. Shroyer. Alterations of p16INK4a protein expression in oral smokeless

tobacco lesions. American Association of Oral Pathology, annual meeting, Kansas City, 2007. 103. Singh M, Mugler K, Torkko KC and Shroyer KR. University of Colorado Health Sciences Center.

Expression of Transferrin Receptor (TR) in a spectrum of normal to malignant breast tissues. 5th Asia Pacific International Academy of Pathology Congress and Chapter of Pathologists Annual Scientific Meeting 27th - 31st May 2007 Singapore.

104. Reno EM, Shroyer KR, Bradford AP. Analysis of protein kinase C delta (PKCδ) expression in endometrial tumors. The Endocrine Society’s 89th annual meeting, June 2-5, 2007, Toronto.

105. MacLean PS, Gilman K, Johnson G, Tarbutton E, McDaniel S, Elder BF, Jackman M, Shroyer KR, Schedin P. Obesity enhances mammary tumor progression in ovariectomized rats. The Endocrine Society’s 89th annual meeting, June 2-5, 2007, Toronto.

106. Barrera J, Greer R, Shroyer KR. RF014: P53 and Hormonal Receptors Express Adenoid Cystic Cancer. American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting. Washington D.C., Sept 16-19, 2007.

107. Lann M, Thomison J, Behbahkt K, Spillman M, Shroyer KR, Singh M. Co-association of Brenner and mucinous tumors of the ovary: two cases illustrating a spectrum. 5th Asia Pacific International Academy of Pathology Congress, Singapore, May 2007.

108. Chain JR, Song JI-T, Shroyer KR. Changes in p16 & Rb confirm HPV-mediated oropharyngeal SCC. American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting. Washington D.C., Sept 16-19, 2007.

109. KR Shroyer, DL Dehn, P Homer, KC Torkko, M Singh, C Thompson, D Franquemont. Does p16INK4a and/or HPV in Cervical Cytology Serve as a Marker of Underlying High Grade Dysplasia on Colposcopic Biopsy. 55th Annual Scientific Meeting of the American Society for Cytopathology. Nov 2-6, 2007. Cancer Cytopathol. 111: 382 (2007)

110. DL Dehn, HS Currens, KM Scaff, KR Shroyer. Evaluation of ProEx C and HPV Testing as Diagnostic Adjuncts to Cervical Cytology for the Detection of Underlying High Grade Dysplasia in a Clinical Setting. 55th Annual Scientific Meeting of the American Society for Cytopathology. Nov 2-6, 2007. Cancer Cytopathol. 111: 388 (2007)

111. P.S. MacLean, E.D. Giles, G.C. Johnson, S.M. McDaniel, B.K. Fleming-Elder, K.A. Gilman, A.G. Andrianakos, M.R. Jackman, K.R. Shroyer, P.J. Schedin. A Surprising Link Between the Energetics of Weight Gain and the Progression of Mammary Tumors in a Model of Postmenopausal Breast Cancer. NAASO Annual Scientific Meeting, October 3-7, (2008)

112. ED Giles, G Johnson, SM McDaniel, B Fleming, K Gilman, A Andrianakos, M Jackman, KR Shroyer, P Schedin, PS. MacLean. Cytokine profiling of Lean and Obese rats in a model of postmenopausal breast cancer. NAASO Annual Scientific Meeting, October 3-7, (2008)

113. Redente, E.F., Dwyer-Nield, L.D., Rice, P., Agarwal, R., Pao, W., Whitsett, J., Merrick, D., Shroyer, K.R., Freed, B., and Malkinson, A.M. Signals from solid peripheral tumors alternatively activate bone

marrow macrophages before they enter the circulation to associate with tumors. AACR proceedings, Abstract # 1529, 2008.

114. PN Samarawardana, KR Shroyer. Co-Localization Of p16INK4a And MIB-1 Distinguishes High Grade Premalignant Lesions from Tuboendometrial Metaplasia In Cervical Mucosa. 2009 Annual Meeting of the United States and Canadian Academy of Pathology.

115. E.I. Chen, M. Titmus, M. Singh, K.R. Shroyer. Proteomic studies of the origin of ovarian serous carcinoma. 100th Annual Meeting of the American Association for Cancer Research, April 18-22, 2009.

116. P.K. Avti, M. Swierczewska, S. Rajamani, S. Burke, K.R. Shroyer, B. Sitharaman. Molecular Imaging and targeted therapy with the antibody functionalized Gd@SWNT. 100th Annual Meeting of the American Association for Cancer Research, April 18-22, 2009. 100th Annual Meeting of the American Association for Cancer Research, April 18-22, 2009.

117. M. D'Aria, E. Chiou, M. Singh, G. Maini, S. Burke, S. Liang, B. Tringler, K.R. Shroyer. B7-H4 (DD-O110) is overexpressed in endocervical adenocarcinoma in situ and invasive adenocarcinoma. 100th Annual Meeting of the American Association for Cancer Research, April 18-22, 2009.

118. J. Du, C.L. Leonhard-Melief, H. Takeuchi, K.R. Shroyer, M. Dlugosz, R.S. Haltiwanger, B.C. Holdener. O-Fucosylation of Thrombospondin type 1 repeats is required to maintain epiblast pluripotency and restrict EMT during mouse gastrulation. 16th International Society of Developmental Biologists Congress September 6-9, 2009.

119. Pending Case Reports: Tools for Reducing Turnaround Time and for Practice Improvement. M. Singh, K. Dasilva, S. Zee, K.R.Shroyer. Annual Meeting of the College of American Pathologists, Washington DC. Arch Pathol Lab Med 133:64, October 2009

120. M. Singh, G. Maini, A. Heimann, S. Hwang, K.R. Shroyer. Telecytology for immediate assessment of CT and EUS guided fine needle aspirations: Advantages and pitfalls. American Society for Cytopathology Annual Meeting, Denver, CO, November 13-17, 2009.

121. P. Samarawardana, D. Dehn, M. Singh, K. Torkko, D. Franquemont, C. Thompson, L. Gaido, K.R. Shroyer. p16INK4a is Superior to HPV Testing in Cervical Cytology for Prediction of Underlying High Grade Dysplasia. American Society for Cytopathology Annual Meeting, Denver, CO, November 13-17, 2009.

122. J. Du, C.L. Leonhard-Melief, H. Takeuchi, K.R. Shroyer; M. Dlugosz, R.S. Haltiwanger, B.C. Holdener. O-Fucosylation of Thrombospondin type 1 repeats maintains pluripotency of epiblast and balances differentiation during mouse gastrulation. 2009 Annual Meeting of the Society for Glycobiology, November 12-15, 2009, San Diego, CA

123. A. Goldberg, S. Burke, K.R Shroyer. B7-H4 protein expression in invasive ductal carcinoma and its association with tumor progression. AACR NCI EORTC Molecular Targets and Cancer Therapeutics Conference, Boston, MA November15-19, 2009.

124. M Singh, J. Liu, J. Lu, KR Shroyer, C. Tornos. Correlation of Oncotype Dx Recurrence Score and Receptor Assessment With Histologic Parameters And ER/PR/Her-2 Status. 2010 Annual Meeting of the United States and Canadian Academy of Pathology.

125. A. Goldberg, S .Burke, G. Diedrich, K. R. Shroyer. B7-H4 Protein Expression in Ductal Carcinoma and its Role in Immunomodulation and Tumor Progression. Cambridge Health Institute, 13th Annual Characterization, Purification, and Screening meeting., Coronado CA, January 13-14, 2010.

126. M. Karaayvaz, T. Pal, B. Song, C. Zhang, P. Geogakopoulos, S. Mehmood, S. Burke, K. Shroyer, J. Ju. Prognostic values of microRNAs in patients with Dukes’ b and c colon cancer. ASCO Annual Meeting. Chicago, June 4-8, 2010.

127. M.A. Titmus, E. Hatchwell, K.R. Shroyer. Enrichment of HPV-integrated gDNA from FFPE tissue for next-generation sequencing. 26th Annual Papillomavirus Conference, Montreal, Canada, July 3-8, 2010.

128. M. Singh, S. Burke, A. Akalin, K.R. Shroyer. Dual localization of p16INK4a and Ki-67 improves specificity for HSIL and AGUS. American Society for Cytopathology Annual Meeting, Boston, MA, November 12- 16, 2010. Cancer Cytopath. 118: 340-41, 2010.

129. P.K. Avti, Y. Talukdar, K.R Shroyer, B. Sitharaman. Towards gadolinium-single walled carbon nanotubes as non-toxic MRI contrast probes, ICB&DD Symposium, Stony Brook University, Oct 14, 2010.

130. J. Keller, S.K. Batajoo, K.R. Shroyer, C. Chandler, M.J. Hayman, E.L. Chan. Ron tyrosine kinase synergizes with EGFR to confer aggressive phenotype in head and neck cancers. 102nd Annual Meeting, American Association for Cancer Research, Orlando FL, April 2-6, 2011, Proc. Am. Assn. Cancer Res.

131. M. Karaayvaz, C. Zhang, S. Mehmood, P. Geogakopoulos, S. Burke, K.R. Shroyer, S. Lang, J. Ju. Expression of miR-205 is significantly associated with prognosis of endometrial cancer. 102nd Annual Meeting, American Association for Cancer Research, Orlando FL, April 2-6.

132. E. Chen, S. Mehmood, S. Burke, J. Chu, L.Fernandez-Escobar, D. Pal, K.R. Shroyer. Immunohistochemical validation of SCCA1/2 expression in cervical carcinoma. 27th International Papillomavirus Conference Berlin, Germany, September17-22, 2011.

133. G. Pagnotti, B. Adler, D.E. Green, M.E. Chan, K. R. Shroyer, W. Beamer, J. Rubin, C.T. Rubin. Preservation of Bone Mass and Life Expectancy in an Aged Murine Model of Spontaneous Granulosa Cell Ovarian Cancer Following Daily Bouts of Low Magnitude Mechanical Signals. 11th International Conference on Cancer-Induced Bone Disease (CIBD) Chicago IL, November 30 – December 3, 2011.

134. H. Ren, K. Park, R. Pan, K.R. Shroyer, W. Waltzer, Y. Pan. Image Guided 3D OCT for Early Diagnosis of Carcinoma in situ of the Bladder. SPIE BiOS conference on Optical Coherence Tomography and Coherence Domain Optical Methods in Biomedicine XVI Conference BO200, San Francisco, CA, January 2012.

135. P. K. Avti, Y. Talukdar1, E. D. Caparelli, K. R. Shroyer, B. Sitharaman. Gadolinium-Catalyzed Carbon Nanotubes as Advanced Magnetic Resonance Imaging Nanoprobes. 2011 Biomedical Engineering Society Annual Meeting, Hartford, CT, October 12-15, 2011.

136. J. Davis, S. Mehmood, V. Nayi, S. Burke, B. Nemesure, K.R. Shroyer, M. Singh. DCIS Recurrence Prediction: A Search For The Holy Grail. United States and Canadian Academy of Clinical Pathology, annual meeting, Vancouver, BC, March 17-23, 2012.

137. C. Patel, B. Harmon R. Soslow, K. Garg , D. DeLair, S Hwang, J Liu, S Zee, K. Shroyer, S. Burke, C. Tornos . Interobserver agreement in the diagnosis of ovarian carcinoma types: Impact of sub-specialization. United States and Canadian Academy of Clinical Pathology, annual meeting, Vancouver, BC, March 17-23, 2012. Modern Pathol 25, suppl 2, 292A

138. P.K. Avti, Y. Talukdar, M. Sirotkin, K.R Shroyer, B. Sitharaman. Towards Single-walled nanotubes-based Theranostics: Pharmacodynamics of single-walled carbon nanotube gadolinium complexes, Biomedical Engineering Society Annual Meeting, Atlanta, Oct 24-27, 2012.

139. M. Mathison, R. Gersch, A. Nasser, M. Korman, M. Fourman, N. Hackett, L. Qian, D. Srivastava, K.R. Shroyer, Y. Ma, R. Crystal, T. Rosengart. In Vivo Cardiac Cellular Reprogramming Efficacy is Enhanced by Angiogenic Preconditioning of the Infarcted Myocardium. American Heart Association Annual Meeting, Los Angeles, CA, Nov 5, 2012.

140. L.F. Escobar-Hoyos, E. Chen, J. Yang, J. Zhu, S. Burke, K.R Shroyer. Molecular classification of cervical intraepithelial neoplasia and carcinoma: Proteomic discovery and immunohistochemical validation. American Society of Cytopathology National Meeting, 2012 Las Vegas, NV, Nov 4th.

141. Stage Specific and Progression Cervical Cancer Biomarkers: Discovery and Histologic Validation. L. Escobar-Hoyos, S. Burke, E. Chen, K.R. Shroyer, 28th International Papillomavirus Conference, San Juan, Puerto Rico, Dec 3rd. 2012.

142. S. Kanakia, J. Toussaint, S.M. Chowdhary, B. Adewale, T. Tembulkar, K.R. Shroyer, W. Moore, B. Sitharaman. Preclinical In Vitro and In Vivo Assessment of Novel Graphene Based MRI Contrast Agent. International Society for Magnetic Resonance in Medicine annual meeting, Salt Lake City, Utah, April 20-26, 2013.

143. S. Kanakia, J. Toussaint, S.M. Chowdhary, B. Adewale, T. Tembulkar, K.R. Shroyer, W. Moore, B. Sitharaman. Dose Dependent Acute toxicity, Biodistribution, Hematological Effects, and Elimination of Dextran Functionalized Graphene Nanoplatelets. Biomedical Engineering Society (BMES) Annual Meeting, September 25-28, 2013, Seattle, Washington.

144. D. Mockler, LF Escobar-Hoyos, A Akalin, S Burke, AL Shroyer, KR Shroyer Keratin 17 is overexpressed and has prognostic value in endocervical glandular neoplasia. EUROGIN 2013, Nov 3-6. Florence, Italy.

145. M. Mo, A.L. Shroyer, E. Regenbogen, K.R. Shroyer. Keratin 17 may be a novel prognostic marker independent of HPV status for head and neck squamous cell carcinomas. EUROGIN 2013, Nov 3-6. Florence, Italy.

146. G.M. Pagnotti, M.E. Chan, B.J. Adler, K.R. Shroyer, C.T. Rubin. Immunomodulatory Role of Mechanical Signaling in Regulating the Expansion of Hematopoietic Precursors in an Early Stage Murine Model of Multiple Myeloma. 13th International Conference on Cancer-Induced Bone Disease (CIBD 2013). November 6-9, 2013, Miami, FL.

147. D. Pandya, K.R. Shroyer, M.O. Korman, R.H. Young, J. Davis, C. Tornos C. Monoclonal antibody for PAX-8 in mesothelial lesions of the peritoneum: A study of 39 cases. Annual meeting of the United States and Canadian Academy of Pathology, San Diego, March 1-7, 2013.

148. C. Liu, D. Balakrishnan, A. Heimann, L. Birney, S. Zee, C. Tornos, M. Singh, K.R. Shroyer, J. Liu. ThinPrep CytoLyt Fixation Has No Effect on ER and Cytokeratin Staining on Normal Breast Tissue. Annual meeting of the United States and Canadian Academy of Pathology, San Diego, March 1-7, 2013.

149. D.C. Mockler, L.F. Escobar-Hoyos, S. Burke, A.L. Shroyer, J. Romeiser, K.R. Shroyer. Keratin 17 Urothelial Neoplasia and its Potential Use as a Diagnostic Biomarker. Annual meeting of the United States and Canadian Academy of Pathology, San Diego, March 1-7, 2013 (submitted).

150. R. Merkin, A.L. Shroyer, C.R. Rizk, S. Burke, J.L. Romeiser, K.R. Shroyer. Cytokeratin 17 Trends Toward Over Expression in Triple-Negative Breast Carcinoma but is unrelated to

Sox2 Expression. Annual meeting of the United States and Canadian Academy of Pathology, San Diego, March 1-7, 2013 (submitted).

151. S. Kanakia, D. M. Hoang, J. Toussaint, S.M. Chowdhury, S. Lee, K.R. Shroyer, W. Moore, B. Sitharaman, Y. Z. Wadghiri. Safety and Efficacy Evaluation Of A Novel Graphene-Based Nanoparticles as an MRI Blood Pool Agent. annual meeting of International Society for Magnetic Resonance in Medicine, Milan, Italy, May 10-16, 2014. (submitted).

152. S. Lee, J. Toussaint1, S. Kanakia1, S.M. Chowdhury, K.R. Shroyer, W. Moore, B. Sitharaman. Nephrotoxicity Assessment of A Novel Graphene-Based Magnetic Resonance Imaging Contrast Agent in Chronic Renal Failure Rodent Models. Biomedical Engineering Society (BMES) Annual Meeting, October 22-25, 2014, San Antonio.

153. S. Kanakia, D.M. Hoang, J. Toussaint, S. Lee, S.M. Chowdhury, K.R. Shroyer, W. Moore, Y.Z. Wadghiri, B. Sitharaman. Chronic Toxicity of Dextran Functionalized Graphene Nanoparticles and Their Potential as Highly Efficacious Blood Pool Contrast Agent for Magnetic Resonance. Biomedical Engineering Society (BMES) Annual Meeting, October 22-25, 2014, San Antonio.

154. M. Altieri, K.R. Shroyer, A. Pryor, G. Pagnotti, M.L. Chan, M. Korman, M. Talamini, D. Telem. The Association between Sleeve Gastrectomy and Histopathologic Changes Consistent with Esophagitis in a Rodent Model. 2014.

155. G.M. Pagnotti, B.J. Adler, E. Chan, M. Korman, K.R. Shroyer, C.T. Rubin. Osteopenia and Osteolysis Resulting from Multiple Myeloma Partially Suppressed through Low Intensity Mechanical Signals ASBMR 2014 Annual Meeting, September 12-15, 2014, Houston, Texas.

156. N. Yang, C. Liu, L. Li, J.E. Fitzpatrick, E.C. Jones, D.A. Norris, A. Liu, R.A. Clark, D.R. Roop, K.R. Shroyer, J. Chen Planar cell polarity effector gene INTU mediates the formation of basal cell carcinoma through orchestrating ciliogenesis and Hedgehog signaling. 2015 Society for Investigative Dermatology Annual Meeting, ID meeting, Atlanta, May 6-9, 2015.

157. L. Escobar-Hoyos, K.R. Shroyer. Keratin 17: Cervical Cancer Prognostic Marker Promotes p27-Nuclear Export and Tumor Growth. Experimental Biology 2015, Boston Massachusetts. March 29- April 1, 2015.

158. G.M. Pagnotti PhD, B.J. Adler, M.E. Chan, K.R. Shroyer, J. Rubin, C.T. Rubin. Low Intensity Mechanical Signals Slow Tumor Progression and Osteolysis in a Murine Model of Multiple Myeloma. ASBMR, April 2015.

158. R. Shah, L.F. Escobar-Hoyos, K.R. Shroyer. Keratin 17 maintains proliferation by binding to p27KIP1 and facilitating its nuclear export. AACR annual meeting, Philadelphia, April 18-22, 2015.

159. Wu M. and Shroyer K.R. Strategies for building a successful ultrasound guided FNA practice in Department of Pathology- Experience at Stony Brook University Hospital. Submitted, annual meeting of the American Society for Cytopathology. Chicago, November 13-16, 2015.

160. S. Lee, S. Kanakia, J. Toussaint, P. Kulkarni, S. Mullick Chowdhury, S. Khan, K.R. Shroyer, W. Moore, B. Sitharaman. Nephrotoxicity of Dextran Functionalized Graphene Nanoparticles and Their Potential as Magnetic Imaging Contrast Agents for Renal Abnormalities. TechConnect World Innovation Conference, Washington DC, April 16, 2015.

161. Y. Gao, E.A. Vanner, L.F. Escobar Hoyos, C. Metter, D. Coldren, T. Kurc, K.R. Shroyer, J. Saltz. (2015) 3D Quantitative Morphological Characterization of Pancreatic Carcinoma Nuclei. Association for Pathology Informatics 2nd World Congress: Pathology Informatics Summit 2015, Pittsburgh, PA. May 5-8, 2015.

162. J. Cohen, D. Pareto, C. Bernstein, P. Farelly, P. Fisher, D. Franceschi, C. Rizk, W. Scherl, K.R. Shroyer, S.Vallabhajosula, A. Biegon. High contrast visualization of breast cancer lesions with [11C]vorozole PET. San Antonio Breast Cancer Symposium 2015.

163. L.F. Escobar-Hoyos, R. Shah, L. Roa-Peña, E. A. Vanner, N. Najafian, A. Banach, E. Nielsen, R. Al-Khalil, AAkalin, D. Talmage, K.R. Shroyer. Beyond Hpv In Cervical Cancer: The Unexpected Oncogenic Role Of Keratin 17. 30th International Papillomavirus Conference & Clinical and Public Health Workshops (HPV 2015), Lisbon, Portugal - September 17-21, 2015.

164. L.F. Escobar-Hoyos, E. Nielsen, R. Shah, R. Al-Khalil, L. Roa-Peña, E. A. Vanner, D. Talmage, K.R. Shroyer. Nuclear Keratin 17 Regulates Cervical Tumor Vascularization By De Novo Gene Transcription. 30th International Papillomavirus Conference & Clinical and Public Health Workshops (HPV 2015), Lisbon, Portugal - September 17-21, 2015.

165. K.R. Shroyer, L.F. Escobar-Hoyos, M. Mo, E. A. Vanner, J. Romeisser, A. Akalin, L. Shroyer. Keratin 17 is a Prognostic Marker In Both Cervical And Head And Neck Squamous Cell Carcinomas (SCCs). 30th International Papillomavirus Conference & Clinical and Public Health Workshops (HPV 2015), Lisbon, Portugal - September 17-21, 2015.

166. R. Khatami, MD, A. Heimann, MD, S. Hwang, MD, K.R. Shroyer, MD, PhD, M. Wu, MD, PhD. ThyroSeq Application Study For Indeterminate Thyroid FNAs; Experience at a University Hospital. USCAP Conference, Seattle, March 12-15, 2016.

167. N.W. Kim, S.Gangakhedkar, T. Nguyen, S. Jahanfard, P. Vichi, L.F. Escobar-Hoyos, and K.R. Shroyer. Multiplex Protein Biomarker test for Cervical Cancer. ASCCP Annual Meeting, New Orleans, April 13-16, 2016

168. N.W. Kim, S. Jahanfard, B. Sunkel, S. Gangakhedkar, C. Todd, P. Vichi, L.F. Escobar-Hoyos, and K.R. Shroyer. A self-collection device for cervical cytology: iPap. ASCCP Annual Meeting, New Orleans, April 13-16, 2016

169. R. Khatami, MD, A. Heimann, MD, S. Hwang, MD, K.R. Shroyer, MD, PhD, M. Wu, MD, PhD. ThyroSeq Application Study For Indeterminate Thyroid FNAs; Experience at a University Hospital. ASCP 2016 Annual Meeting September 14-16, 2016 in Las Vegas, NV.

170. L. Escobar-Hoyos and K.R. Shroyer. Discovery and validation of keratin 17 as a prognostic cancer biomarker. 2016 World Life Science Conference, Beijing, China. Nov. 1st-3rd, 2016.

171. L.F. Escobar-Hoyos, C. Leiton, E. Vanner, L. Roa-Pena, J. Li, S. Powers, A. Akalin, J. Bandovic, P. Bailey, D. Chang, R. Moffitt, J.J. Yeh, A. Biankin, K.R. Shroyer. Keratin 17 identifies prognostic subtypes of pancreatic ductal adenocarcinoma. AACR annual meeting, April 1-5, 2017 Washington DC.

172. S. Liu, D. Lozeau, K. Haye, L. Roa, P. Uppal1, K.R. Shroyer, L. Escobar-Hoyos. Role of keratin 17 as a potential diagnostic biomarker in melanoma. American Society of Dermatopathology, annual meeting, Baltimore, Oct 26-29, 2017.

173. R. Khatami, C. Metter, A. Heimann, S. Hwang, K.R. Shroyer, M. Wu. Accuracy of Targeted Next Generation Sequencing Panel (tNGS) in Indeterminate Thyroid Fine Needle Aspiration (FNA) Specimens with Surgical Follow Up. United States and Canadian Academy of Pathology, annual meeting, March 17-23, 2018 (submitted).

174. L. Escobar-Hoyos, D. Mockler, and K.R. Shroyer. Keratin 17 (K17) is a prognostic biomarker of cervical cancer: endocervical glandular neoplasia.. Eurogin, Amsterdam, October 10, 2017.

175. A.E. Witbeck1, B. Urquilla1, C.V. Leiton, L. Roa-Peña, K. Haye, L.F. Escobar-Hoyos, K.R. Shroyer. Keratin 17 interacts with the CIP/KIP family of tumor suppressors via domains similar to cyclins in Pancreatic Ductal Adenocarcinoma. Stony Brook Cancer Center, Annual Retreat, Stony Brook University, Nov 3, 2017.

176. D. Fassler, L.F. Escobar-Hoyos, C. Leiton, K.R. Shroyer. Transcriptional upregulation of Keratin 17 in the pathogenesis of pancreatic cancer. Stony Brook Cancer Center, Annual Retreat, Stony Brook University, Nov 3, 2017.

177. L Lucia Roa-Peña, E.A. Vanner, A. Akalin, J. Bandovic, R.A. Moffitt, C. Iacobuzio-Donahue, L.F. Escobar-Hoyos, K.R. Shroyer. From RNA-Seq to Immunohistochemistry: Keratin 17 Defines Pancreatic Cancer Subtypes. Platform presentation. Annual Meeting of the American Society for Investigative Pathology. April 24, 2018.

178. J.P. Fitzgerald, L.A. Bevilacqua, J. Romeiser, N. Mathias, C.K. Stewart, S. Pehling, K.R. Shroyer, A.L. Shroyer. Implementation of a novel, local upper urinary tract cancer quality assurance registry. Annual meeting of the Society of Urologic Oncology, Pheonix, AZ, Nov 28-30, 2018.

179. V. Yang, Y. Liu, J. Kim, K.R. Shroyer, A. Bialkowska. Intestinal epithelium-specific deletion of Klf4 accelerates progression of colitis-associated colorectal cancer through increased genetic instability. (In press, Molec Cancer Res)

180. Q. Wang, K. Shapiro, Y. Lu, K.R. Shroyer, S. Hwang. EZH2 Expression in Rhabdomyosarcoma: A Potential Biomarker and Therapeutic Target. Submitted, 2019 annual meeting of the USCAP.

181. R. Kawalerski, L. Roa-Pena, T. Boyle, C. Leiton, N. Snider, K.R. Shroyer, L.F. Escobar-Hoyos. Oncogenic mechanism of soluble Keratin 17 offers potential therapeutic vulnerability in pancreatic cancer. Presented at AACR: Pancreatic Cancer: Advances in Clinical Care, Boston, MA, September 21-24, 2018.

182. L. Roa-Pena, C. Leiton, S. Babu, E. Vanner, C. Pan, A. Akalin, J. Bandovic, R. Moffitt, L.F. Escobar-Hoyos, K.R. Shroyer. From RNA molecular subtyping to immunohistochemistry and in vivo validation:

Keratin 17 identifies and drives pancreatic cancer aggression. Presented at AACR: Pancreatic Cancer: Advances in Clinical Care, Boston, MA, September 21-24, 2018.

183. C. Leiton, L. Roa-Pena, C. Pan, A. Penson, N. Turkman, R. Moffitt, M. Seeliger, D. Talmage, K.R. Shroyer, L.F. Escobar-Hoyos. Therapeutic targeting of the most aggressive subtype of pancreatic cancer. Presented at AACR: Pancreatic Cancer: Advances in Clinical Care, Boston, MA, September 21-24, 2018.

184. D. Fassler, M. Zhao, G. Mackenzie, R. Gupta, J. Bandovic, L. Pena-Roa, T. Kurc, J. Saltz, L.F. Escobar-Hoyos, K.R. Shroyer. Dissecting inflammatory microenvironment factors driving expression of K17, a hallmark of basal pancreatic cancer. Presented at AACR: Pancreatic Cancer: Advances in Clinical Care, Boston, MA, September 21-24, 2018.

185. C. Pan, C. Leiton, L. Roa-Pena, R. Kawalerski, R. Moffitt, P. Bailey, D. Chung, A. Biankin, P. Singh, K.R. Shroyer, L.F. Hoyos- Escobar. Metabolic rewiring and chemoresistance mechanisms of the most aggressive molecular subtype of pancreatic cancer. Presented at AACR: Pancreatic Cancer: Advances in Clinical Care, Boston, MA, September 21-24, 2018.

Invited Seminars and Lectures (2007-present): 2007 Molecular Markers of Cervical Dysplasia and Carcinoma: Implications for Diagnostic Cytopathology. MSTP Clinical Scientist Dinner Seminar, Stony Brook University Medical Center, October 18. 2008 Human papillomavirus and Cervical Cancer: The Development of a Molecular Pap Test. Institute of

Chemical Biology and Drug Discovery, Stony Brook University. February 29. 2008 Molecular Markers of HPV Infection: The Development of a Molecular Pap Test. Stony Brook Cancer

Center Lecture Series, March 26th. 2008 Molecular Markers of HPV and Cervical Cancer: Implications for Diagnostic Cytopathology and the

Development of a Molecular Pap Test. Department of Pathology, Montefiore Medical Center, April 3rd. 2008 Cervical Dysplasia and Carcinoma: Implications for Diagnostic Cytopathology. MSTP Clinical Scientist

Dinner Seminar, Stony Brook University Medical Center, April 10. 2008 Challenges and Opportunities for Reinvigoration of an Academic Pathology Department. Annual Meeting

of the NE Association for Pathology Chairs, Bermuda, September 13. 2009 p16INK4a as a Diagnostic Tool for Cervical Biopsy and Cytology Specimens. College of American

Pathologists annual meeting, Washington DC, October 11 (satellite seminar sponsored by MTM Laboratories)

2009 The application of p16INK4a immunohistochemical staining in the evaluation of HPV-associated cervical squamous and endocervical lesions, and potential diagnostic pitfalls. Medical Education Seminar, Department of Pathology, University of Utah, November 12

2009 Molecular analysis of cervical dysplasia and carcinoma: Diagnostic pitfalls. Clinical Conference, Department of Pathology, Stony Brook University, December 23.

2010 Cervical Cancer Biomarker Discovery and Validation, K30 seminar speaker, February 8. 2010 Molecular Markers of HPV and Cervical Cancer: Biomarker Discovery and Validation, Pathology Grand

Rounds, University of Vermont, February 24. 2010 Molecular Markers of HPV and Cervical Cancer: Biomarker Discovery and Validation. BIT Life

Sciences’ 3rd World Cancer Congress 2010, June 22, Singapore. 2010 Molecular Diagnoses of Cervical Neoplasia: Biomarker Discovery and Validation. University of Hong

Kong, School of Medicine, June 24, Hong Kong. 2010 Molecular Diagnosis of Cervical Neoplasia: Biomarker Discovery and Validation MSTP Clinical Scientist

Dinner Seminar, Stony Brook University Medical Center, September 14.

2010 Advances in Cervical Cancer Screening: Beyond HPV Testing, Suffolk County Pathology Society Dinner Seminar, Stony Brook, December 9th. 2011 Cytopathology Scientific Session, Chair, United States and Canadian Academy of Pathology, annual

meeting, San Antonio. February 26- March 3. 2011 Long Island University, Brooklyn Campus, Seminar on career opportunities in biomedical research to

STEM (Science, Technology Engineering, and Math) students sponsored by the Predominantly Black Institutions Program, Project QUEST, a division of the United States Department of Education., March 25.

2011 Institute for Chemical Biology & Drug Discovery: Cancer Retreat. Cervical Cancer Biomarker Discovery and Validation, June 24

2011 Molecular Diagnosis of Cervical Neoplasia: Biomarker Discovery and Validation. Molecular Pharmacology Seminar Series, October 25.

2011 Infection and the Molecular Pap Test: Cervical Cancer. Department of Molecular Genetics and Microbiology, annual retreat. Friday, October 14, 2011, Port Jefferson Village Center.

2012 Beyond HPV Testing: Cervical Cancer Biomarker Discovery and Validation. Graduate Program in Genetics, Annual Retreat, Cold Spring Harbor Biology Laboratories, Cold Spring Harbor, NY, May 27.

2012 Molecular Diagnosis of Cervical Dysplasia and Carcinoma: Biomarker Discovery and Validation. OB/GYN Grand Rounds, May 23.

2012 Molecular classification of cervical intraepithelial neoplasia and carcinoma: Proteomic discovery and immunohistochemical validation. Invited Platform presentation, presented by L. Escobar-Hoyos (graduate student, K.R. Shroyer Lab), American Society of Cytopathology National Meeting, Las Vegas, NV, Nov 4th.

2012 Stage Specific and Progression Cervical Cancer Biomarkers: Discovery and Histologic Validation. Invited Platform presentation, presented by L. Escobar-Hoyos (graduate student, K.R. Shroyer Lab), 28th International Papillomavirus Conference, San Juan, Puerto Rico, Dec 3rd.

2013 Keratin 17 Expression in Cervical Glandular and Squamous Neoplasia. Invited platform presentation and session chair: HPV Infection: From Molecular Biology to Diseases. EUROGIN 2013 Congress, Florence, Italy, November 5th.

2013 Cervical Cancer Biomarkers: Discovery and Histologic Validation. Stony Brook MSTP Clinical Scientist Seminar, Stony Brook Medicine, November 20th.

2014 Cervical Cancer Biomarker Discovery and Histologic Validation. Department of Pathology, University of Hawaii. April 2.

2014 Cervical Cancer Biomarker Discovery and Histologic Validation. Department of Pathology Clinical Conference, Stony Brook Medicine. September 3.

2015 Keratin 17 is a prognostic marker in both cervical and head and neck squamous cell carcinomas (SCCs). 30th International Papillomavirus Conference & Clinical and Public Health Workshops (HPV 2015), Lisbon, Portugal - September 17-21.

2015 Beyond HPV In Cervical Cancer: The Unexpected Oncogenic Role Of Keratin 17. 30th International Papillomavirus Conference & Clinical and Public Health Workshops (HPV 2015), Lisbon, Portugal - September 17-21. (presented by PhD graduate student, Luisa Escobar-Hoyos)

2015 Nuclear Keratin 17 Regulates Cervical Tumor Vascularization By De Novo Gene Transcription. 30th International Papillomavirus Conference & Clinical and Public Health Workshops (HPV 2015), Lisbon, Portugal - September 17-21, 2015. (presented by PhD graduate student, Luisa Escobar-Hoyos)

2015 Discovery and mechanistic validation of Keratin 17 as a prognostic biomarker of cervical cancer. November 20, Stephenson Cancer Center Grand Rounds, University of Oklahoma Health Sciences Center, Oklahoma City, OK.

2015 Discovery and mechanistic validation of Keratin 17 as a prognostic cancer biomarker. Macau University of Science and Technology. November 10.

2015 Discovery and mechanistic validation of Keratin 17 as a prognostic cancer biomarker. Southern Medical University Guangzhou. November 13.

2016 Discovery and mechanistic validation of Keratin 17 as a prognostic biomarker of cervical cancer. March 30, Center for Biotechnology Grand Rounds, Georgia Regents University, Augusta, GA.

2016 Rebuilding Basic and Translational Research in an Academic Pathology Department. Annual meeting of the South and Southwest Pathology Chairs, October 26, Maui, Hawaii.

2016 Discovery and validation of keratin 17 as a prognostic cancer biomarker. World Life Science Conference, Organized by the China Association for Science and Technology and the Chinese Union of Life Science Societies, Nov 1-3, Beijing, China.

2017 Discovery and Validation of Keratin 17 as a Prognostic Cancer Biomarker. Visiting Professorship, University of Colorado, Anschutz Medical Center, Aurora, Colorado. Jan 27.

2017 Discovery and validation of keratin 17 as a cancer prognostic biomarker. Icahn School of Medicine at Mount Sinai and Stony Brook University Joint Symposium, Chemical Biology and Drug Discovery, March 17.

2017 Oncogenic roles of nuclear keratin 17: potential implications for development of a novel therapeutic target. ICB&DD Industrial Advisory Board (IAB) consultation meeting, March 24, Stony Brook University.

2017 Discovery and validation of keratin 17 as a prognostic biomarker for cervical cancer. Clinical Conference, Department of Pathology, June 7, Stony Brook University.

2017 Discovery and validation of diagnostic and prognostic biomarkers in cancer: p16 and keratin 17. 3rd International Central American Histology Congress, San Jose, Costa Rica, June 22-24.

2017 Discovery and Validation of Keratin 17 as a Prognostic Cancer Biomarker. Pathology Grand Rounds, New York Medical College, Sept 9.

2017 Discovery and Validation of Keratin 17 as a Prognostic Biomarker and Cancer Therapeutic Target. Molecular & Cellular Pharmacology Fall Symposium, Stony Brook University, Sept 13.

2018 Discovery and validation of keratin 17 as a cancer prognostic biomarker. Annual Cancer Health Disparities Symposium on work with pancreatic cancer, SUNY Downstate Medical Center, Brooklyn, NY. March 2.

2018 Keratin 17 is a novel actionable target in pancreatic ductal adenocarcinoma. Pancreatic Cancer Action Network, Scientific Meeting, San Diego, CA, August 24

2018 Pancreatic Ductal Adenocarcinoma and Neuroendocrine Tumors: Established and Emerging Biomarkers to Guide Diagnosis and Treatment. Long Island Gastrointestinal Cancer Symposium. Stony Brook University Cancer Center, October 20

2018 Keratin 17 is a novel actionable target in pancreatic ductal adenocarcinoma. Institute for Biology and Drug Discovery, Stony Brook University, November 16

Teaching Responsibilities:

Medical & Graduate Students: Alternate Track (MSTP) Pathology, UCDHSC, Course Director, 37 contact hours/year (1992-2005). Lecturer in neoplasia of the endocrine system and gynecologic pathology. Special seminar on "Analysis of Clonality and Telomerase Expression in Endometrial Pathology." Supervisor of student participation in autopsy case analyses. Introductory lecture on “Molecular Markers of Cervical Dysplasia and Carcinoma” MSTP, February 8, 2006. Lecture on Tumor Biomarkers, Spring 2007, Cancer: Experimental and Medical Aspects; PHSC 7530

Medical Students: UCDHSC Pathology 6000, Lecturer in Pathology of Uterine Cervix., Small lab seminar leader, 4

laboratory sessions, 2006-2007. Pelvic Anatomy Review (Uterine and Ovarian Gross Anatomic Pathology, April 24, 2006), Anatomy-Pathology Rounds Fall 2006.

IDPT 5005, small group lab sessions (16 students): Diseases of the Upper GI Tract (10/12/06) Diseases of the Lower GI Tract (10/17/06) Obstructive/Restrictive Lung Disease (04/23/07) Inflammatory Lung Disease and Lung Cancer (05/23/07) Tumors of the Kidney and Urinary Tract (05/24/07) Stony Brook University HBP 531-First year General Pathology, Clinical CPCs (2008-present: two laboratory

sections/year) HBP 531- First year General Pathology, Seminar on Introduction to Pathology (4/16/2010) HBP 531-First year General Pathology, Gross Organ Pathology (2008-present: four laboratory

sections/year) Reproductive System, Seminar on Cervical Dysplasia and Carcinoma (2009-present)

HPD 650-Seminar Series: Clinical Applications of Molecular Medicine (April-May, annual) (Founding Co- director with Dr. Kanakporn Rithidech, and introductory speaker) HBP-511 Pathobiology for Nurse Practitioners (NPs) and Physician Assistants (PAs). Intro to Oncology and Cervical Cancer (December 2011-present)

Pathology Residents: UCDHSC Director of Cytopathology and Surgical Pathology Rotations (4 residents and 2 surgical

pathology fellows/3 month rotation, 4 rotations/year), Cytology Journal Club and Cytology Didactic Series (1991-2002). Lecturer in Molecular Biology, Gynecologic Cytopathology, HPV and Neoplasia, Gynecologic Cytopathology, Fine Needle Aspiration Cytopathology. Teaching is also conducted in the context of direct supervision of fine needle aspirations, Surgical Pathology case sign out and Cytology case sign out.

Graduate Students:

RPSC 7801: Introduction to Reproductive Endocrinology. Lecture: Molecular Basis of Cancer diagnostics.

Cancer Biology (CANCB 7600): Cervical Cancer, viral causation/epidemiology. Histopathology, Pap smears/cytology. Feb 27 and March 1, 2006.

Cancer Biology (CANCB 7600): Molecular Diagnosis of Cervical Dysplasia and Carcinoma. Feb 20, 2007.

School of Pharmacology, PHSC 7530 Cancer: Experimental and Medical Aspects; Tumor Biomarkers March 9th, 2007

MSTP Clinical Scientist Dinner Seminar. Molecular Markers of Cervical Dysplasia and Carcinoma: Implications for Diagnostic Cytopathology, Stony Brook University Medical Center, October 18, 2007

MSTP Clinical Scientist Dinner Seminar Cervical Dysplasia and Carcinoma: Implications for Diagnostic Cytopathology., Stony Brook University Medical Center, April 10, 2008.

HBP-511 Physicians Assistant Pathobiology Course, Intro to Oncology and Cervical Cancer, Dec 14, 2010

Undergraduate Students: Pathologist as a Truth Seeker, SARAS Program, July 10, 2014. Faculty Development: Professional Program Development Program: Seminar on NIH grant applications and review process. May 6, 2010. K30 seminar speaker , Cervical Cancer Biomarker Discovery and Validation, February 8 2010.

Gynecologic Case Review Series: Series Director, 8 contact hours/year. The series reviews current colposcopy clinic cases and surgical case material on a weekly basis, 1996-2003.

Obstetrics and Gynecology Residents: Program Director, "Pathology of the Female Genital Tract"

seminar series (1992-1995). The series consisted of five 1 hour lectures, two given by Dr. Shroyer on the cytopathology of the female genital tract and the histopathology of the uterine corpus.

National: Faculty member and lecturer, American Association for Cancer Research Summer Workshop,

Pathobiology of Cancer, sponsored by the National Cancer Institute, July 13-20, 2003. Supervision of Student, Resident, and Postdoctoral Fellow Research Projects (2007-present): Laurie Kopecky Thomas Graduate Student, Department of Biochemistry and Molecular Genetics.

University of Colorado at Denver and Health Sciences Center. p16INK4a overexpression in HPV-mediated cervical neoplasia. (07/02/07-8/31/08)

Pennie Georgakopoulos Undergraduate Student, Stony Brook University (9/23/07-present) Farah Mohamed Undergraduate Student, Stony Brook University (9/23/07-2009) Saira Mehmood Undergraduate Student, Stony Brook University (9/23/07-present) Jobbin Jacob Undergraduate Student, Stony Brook University (2/21/08-present) Vipul Nayi Undergraduate Student, Stony Brook University (3/24/08-present) Feliks Yartskiy Undergraduate Student, Stony Brook University (9/23/08-present) Matthew Titmus Graduate Student, Molecular and Cellular Biology Program, Stony Brook

University (3/31/08-present) Timour Baslan MSTP student, Stony Brook University (1/1/09-3/31/09) Allison Goldberg Undergraduate Student, Stony Brook University (2008-2010). 2009 recipient of

the URECA Summer Research Program (6/1/09-8/7/09) and the Howard Hughes Medical Institute Undergraduate Summer Research Fellows Program

Gerri Galotti Undergraduate Student, Stony Brook University (6/10/9-6/30/10). Katherine O’Connor Medical Student, Stony Brook University (5/27/10-6/30/11) Peyman Samghabadi Medical Student, Stony Brook University (6/10/10-6/30/11) Bingyin Wang Graduate Student, Molecular and Cellular Biology Program, Stony Brook

University (8/23/10-11/5/10) Analysis of HPV and p16 in cervical neoplasia. Ruchi Shah High School Student, recipient of the 2011 Simons Summer Research Program. Stony Brook University undergraduate student. Simons Fellow Summer 2011- June- August

Undergraduate research rotations (Fall 2013, Spring 2014, Fall 2014, Fall 2015), Cervical cancer biomarker discovery and validation: Co-localization of K17 and p27. Awards: American Association for Cancer Research (AACR) Thomas J. Bardos Science Education Award (2015), 2nd place AACR-Gary J. Miller Undergraduate Prizes for Cancer Research (2015). Best Undergraduate Award, Medicine and Public Health, 2016 American Association for the Advancement of Science (AAAS) Annual Meeting.

Mukit Muntazim Undergraduate Student, Stony Brook University (6/01/10-7/31/12). Howard Hughes Summer Research Scholar, 2011.

Julie Cavallo Graduate student, Molecular and Cellular Pharmacology, graduate student research rotation. Stony Brook University. Cervical cancer biomarker discovery and validation. (2012)

Derek Cheng MD, PhD student, research rotation, MSTP Program, Cervical cancer screening based on immunohistochemical localization of keratin 17 and survivin. Stony Brook University, (6/2012-8/2012)

Ross Merkin Medical Student, Scholarly Concentrations Program/MD with Recognition program. Keratin 17 and stem cells in breast cancer. (6/1/2013-present)

Michelle Mo Medical Student, Scholarly Concentrations Program/MD with Recognition program Keratin 17 and HPV in head and neck squamous cell carcinoma (6/1/2013-5/30/2017)

Lily L. Yung Medical Student, Scholarly Concentrations Program/MD with Recognition program, Effect of Taxoid treatment on breast cancer stem-like cells. Co-mentor with Dr. Emily Chen, Columbia University (9/2013-5/2017)

Anna Banach Graduate student, Molecular and Cellular Pharmacology, research rotation, Spring semester, 2014

Nilofar Najafian Medical Student, Scholarly Concentrations Program/MD with Recogniiton Program. Role of keratin 17 in sustained cell cycle progression and tumor angiogenesis (6/2013-8/2015)

Erik Nielsen Medical Student, Scholarly Concentrations Program/MD with Recognition program, Keratin 17 as a biomarker of EMT and tumor aggression (6/2014-present)

Ramsey Al-Khalil MSTP student, Stony Brook Medicine, research lab rotation (7/14/14-7/2016) Shula Scheckter Medical Student, Stony Brook Medicine, Keratin 17 as a biomarker of pancreatic

ductal carcinoma. (6/2014-5/2016) Juan Carlos Silva Graduate Student, Science in Genomics, Autonomous University of Ciudad

Juárez (UACJ), Chihuahua, Mexico. Cervical Cancer screening based on immunocytochemical localization of keratin 17. (July 1-August 31, 2014)

Jinelle Wint Graduate student, Molecular and Cellular Pharmacology, graduate student research rotation. Stony Brook University. Cervical cancer biomarker discovery and validation. (03/23/2015-05/20/2015)

Kelvin Kwofie Medical student, Scholarly Concentrations Program. 2015-2017. Immunocytochemical analysis of keratin 17 in cytology specimens.

Sarah Gottesman Schreiber High School, Port Washington, K17 as a negative prognostic biomarker for cancer progression (July-August, 2016)

Ji Dong (Karen) Bai Medical Student, Scholarly Concentrations Program/MD with Recognition program. Association of Keratin 17 with survival in renal cell carcinoma. (6/1/2016-present)

Simran Gupta Senior Honors Thesis Sponsor: Regulation of IGF-1, COX-1 and COX-2 expression by Keratin 17 SANT domain. (Jan 2017-May 2018)

Kennelia Mellanson Senior Honors Thesis Sponsor: Hypoxia and Keratin 17 in pancreatic ductal adenocarcinoma (Feb 2017-May 2018)

Taryn Boyle Medical Student, Scholarly Concentrations Program/MD with Recognition program, Keratin 17 in primary versus metastatic pancreatic ductal adenocarcinoma (5/2017-present)

Ryan Kawalerski Undergraduate Student, Stony Brook University. Post-translational modifications mediate K17 nuclear translocation in pancreatic ductal adenocarcinoma, Sept 2017-present. Recipient of the 2018 Barry Goldwater Scholar (the nation’s highest award to undergraduate students in science, mathematics and engineering) and the 2018 Chhabra-URECA Scholarship Award (SBU)

Graduate Program in Public Health Faculty Advisor

Chris Shackles Graduate student, Masters in Public Health, Stony Brook University, 01/09/09-2012-2014

Graduate Thesis Advisor (2007-present):

Luisa F Escobar-Hoyos Graduate student, Molecular and Cellular Pharmacology, Fulbright Colombia Scholar. Stony Brook University (Thesis advisor) Molecular markers of cervical transformation and carcinoma. (5/01/11-11/04/15). Awards: NIH Travel Award, International Papillomavirus Conference. 2012, Pfizer Travel Scholarship, International Papillomavirus Conference, 2015. Best Poster Award, Pancreatic Diseases. Gordon Research Conference, 2015. Young Academic Inventors Award, National Academy of Inventors, 2017.President’s Award to Distinguished Doctoral Student, Stony Brook University, 2016.

Danielle Fassler Graduate Student, MSTP, Stony Brook University, 2015-present. Chun-Hao Pan Graduate Student, Molecular and Cellular Biology Program, Metabolic and

chemoresistant functions of keratin 17 in pancreatic cancer. Stony Brook University, 2017-present.

Member Thesis Advisory Committee (2007-present): Haiyan Zhai, M.D. Graduate student, Molecular and Cellular Biology Program, Stella Tsirka Lab,

Stony Brook University. 2007. Roles of tPA and annexin II in glioma invasion. Yan Song Graduate student, Molecular and Cellular Biology Program, Howard Crawford

Lab, Stony Brook University. 2008. Transcriptional regulation of MMP-7 in pancreatic cancer.

Onika Murray Graduate student, Molecular and Cellular Pharmacology, Basil Rigas Lab, Stony Brook University. 2011. The Reduction of Pancreatic Cancer by Phosphosulindac

Timour Baslan Graduate Student, Stony Brook University, Molecular and Cellular Biology Program, Stony Brook University (Thesis Committee Chair)

(06/01/11-2013) Single Cell Genome Interrogation. Thesis defense completes 8/2/2013.

Dun Li (Chair) Graduate Student, Molecular and Cellular Biology Program, Ute Moll Lab, Stony Brook University, 2012-2014. The effects of mutant p53 overexpression and depletion in cancer cells. Thesis defense completed 3/14/2014.

Mihriban Karaayvaz Graduate Student, Molecular and Cellular Biology Program, Jingfang Ju Lab, Stony Brook University, 2012-May 10, 2013. miR-129 promotes apoptosis and enhances chemosensitivity to 5-Fluorouracil in colorectal cancer. Thesis defense completed on 5/10/2013.

Sayan M. Chowdhury (Chair) Graduate Student, Molecular and Cellular Biology Program, Bilaji Sitharaman Lab, Stony Brook University, 2013-2014. PEG-DSPE coated graphene nanoribbons as drug delivery agents for HPV mediated cancers.

Thesis defense completed on 7/22/2014. Brittany Carol Graduate Student, Molecular and Cellular Biology Program, Lina Obeid Lab,

Stony Brook University, 2013-2015. Regulation of Sphingosine Kinase 1 by p53-Dependent Proteolysis. Thesis defense completed on 5/18/2015.

Shruti Kanakia Graduate Student, Biomedical Engineering Program, Bilaji Sitharaman Lab, Stony Brook University, 2013. Development of graphene as a MRI contrast agent. Thesis defense completed on 12/19/2014.

Gabriel Pagnotti Graduate Student, Biomedical Engineering Program, Clint Rubin Lab, Stony Brook University, 2013-present. Mechanical Signaling Preserves Bone Mass by Mitigating Bone Resorption in Murine Models of Cancer via Alteration of the Bone Marrow Microenvironment without Compromising Subject Survival. Thesis defense completed on 8/11/2015.

Mohamad Adada Graduate Student, MSTP, Lina Obeid Lab, Stony Brook University, 2013-2015. Thesis defense completed on 4/15/2015. Jeremy Miyauchi Graduate Student, Molecular Pharmacology Program, Stella Tsirka Lab, Stony

Brook University, 2013-2015. Completed thesis defense on 10/2/2015 Chih-Li Lin Graduate student, Molecular & Cellular biology (MCB) program, Cuigui Mao

Lab, ACER1 expression in Squamous cell carcinoma, 2014-2017. Completed thesis defense on 6/28/2017.

Michael Caponegro Graduate student, Molecular & Cellular Biology (MCB) program, Stella Tsirka Lab. Validation of monocyte-specific ablation of NRP1 in glioblastoma and characterization of transcriptional changes.

Robert Morabito Graduate student, Molecular & Cellular Biology (MCB) program, Ben Martin and Dave Matus Lab. Identification of conserved, cell cycle regulated, mechanisms of invasive cells during development and cancer.

Nuri Kim MD/PhD Student, Graduate Program in Genetics, Dave Matus Lab. Cell-cycle state during cell invasion in the C. elegans anchor cell; use of the sex myoblast to study how cell-cycle state relates to migration vs. proliferation.

Postdoctoral Residents/Fellows (2007-present): James Suh, MD Pathology Resident, SBUMC, 2009-2010. Current position: Assistant Professor

of Pathology, New York University School of Medicine, effective July, 2011. Laura Viens MD Preventative Medicine Resident, SBUMC, 2014-2016. Analysis of Keratin 17 as

a prognostic biomarker in cervical cytology. Elizabeth Vanner, PhD Current position: Post-Doctoral Associate Statistician/Clinical Outcomes

Researcher, Departments of Pathology and Bioinformatics, SBUMC, 2014- 2017.

Cindy Leiton, PhD Postdoctoral Research Fellow, Genetic and pharmacologic inhibition of the functional domains of keratin 17 in pancreatic cancer.

Rajarsi Gupta, MD Pathology Informatics Fellow., Digital imaging of keratin 17 in pancreatic cancer. (July 2017-present)

Designated Faculty Mentor (2007-present): Sabine Brouxhon, MD Assistant Professor, Department of Emergency Medicine, SBUMC, 2008-2012

Current position: Professor, Department of Surgery, University of Kentucky Emily Chen, PhD Assistant Professor, Department of Pharmacological Sciences, SBUMC, 2011-

2014. Curretn position: Senior Direcotr, Thermo Fisher Precision Medicine Angelique Corthals, PhD Assistant Professor, Department of Sciences, John Jay College of Criminal

Justice, 2011-2013. Current position: Associate Professor, John Jay College of Criminal Justice

John Fitzgerald, MD Assistant Professor, Department of Urology, SBUMC, 2014- 2017. Current position: Associate Professor, Department of Medicine, Renaissance School of Medicine

RESEARCH FOCUS: Over the course of my career, I have led a research group that has focused on the discovery and validation of cancer biomarkers with the underlying goal of enhancing the diagnostic accuracy for cancer in Surgical Pathology and Cytopathology specimens. Board Certified in Anatomic and Clinical Pathology (1991), with subspecialty certification in Cytopathology (1995), I served as the Director for Cytopathology and Surgical Pathology and as the vice chair for Anatomic Pathology at the University of Colorado Health Sciences Center. Following my recruitment to Stony Brook University Medical Center as Chair of the Department of Pathology in 2007, I remained active in the practice of Surgical Pathology and Cytopathology, took on additional roles as the Director of the Stony Brook BioBank and Research Histology Core Laboratories, and continue to lead a translational research program that trains graduate students, postdoctoral research fellows, medical students, and residents in advanced histologic and molecular approaches for tissue-based cancer research. At Colorado, I invented the method of DNP labeling of nucleic acid probes, was a pioneer in the development of methods for in situ hybridization of mRNAS in the early 1980s, and was the first to report the molecular analysis of x-chromosome inactivation in archival tissues as a marker of clonality. I also participated in the early validation of tyramide-based signal amplification technology for in situ hybridization and high sensitivity immunohistochemistry.

Diagnostic Cancer Biomarkers: A major focus of my translational research at the University of Colorado from 1991-2007 was in the identification and validation of objective molecular approaches to improve diagnostic accuracy in surgical pathology and cytopathology. The ultimate aim of this work was to provide pathologists with molecular markers that can be integrated and interpreted in the context of tissue histopathology and cytopathology. My lab was the first to report the analysis of telomerase expression as a biomarker of cervical cancer, provided the first comprehensive evaluation of p16 expression in cervical neoplasia, and pioneered the development of molecular diagnostic adjuncts to improve diagnostic accuracy for HSIL and cervical squamous cell carcinoma. Under my direction, the Surgical Pathology service at the University of Colorado became the first lab in the world to deploy p16 testing in pathology diagnostic laboratories to improve diagnostic accuracy. I was also the first to report that survivin, an inhibitor of apoptosis, is a prognostic biomarker in breast cancer and my lab also was the first to identify NQO1 as a potential biomarker of pancreatic ductal adenocarcinoma. Finally, based on in silico, in vitro, and immunohistochemical studies, my lab was the first to report that B7-H4, a regulator of T cell activation, is highly overexpressed in cancer and is a sensitive biomarker of ovarian, uterine, breast, and pancreatic adenocarcinoma. Prognostic Cancer Biomarkers (2007-present): Using cervical cancer as a model system to identify prognostic markers, my group discovered by mass spectrometry and validated by immunohistochemistry that keratin 17 (K17) is more accurate than clinicopathologic assessment to predict patient survival. Although K17 was previously known to provide mechanical support in normal epithelial cells, we found that K17 also has oncogenic functions, not only in cervical cancer, but also a wide range of cancer types, including pancreatic ductal adenocarcinoma (PDAC). To identify the molecular mechanisms through which K17 controls fundamental aspects of tumor cell biology and thus, is a rational target for therapeutic intervention in PDAC, I assembled an inter-institutional team of investigators that have tremendous experience with orthotopic and transgenic mouse models of pancreatic cancer, the development of PDAC organoid cultures and patient-derived xenografts, and RNA-Seq data analysis and predictive modeling. Our studies, currently funded by the Pancreatic Cancer Action Network (PanCAN) are the culmination of our collaborative efforts to further understand the mechanisms through which K17 promotes tumor aggression and to provide a rationale for targeting K17 in PDAC.